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Abstract

THE EFFECT OF VARIABILITY IN SUBSTANCE ABUSE AND DEPENDENCE
TERMINOLOGY ON PHYSICIANS’ PRESCRIBING DECISIONS
By Lisa Rochelle Burroughs Phipps
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2006
Major Directors: Patricia W. Slattum, Pharm.D., Ph.D., Cynthia K. Kirkwood, Pharm.D.
Associate Professors, Department of Pharmacy

Prescription drug abuse is a continuing problem in the United States. Educating
physicians on issues related to prescription drug abuse is a key factor in preventing and
treating this problem. High variability has been found in substance abuse terminology in
the literature, textbooks, and FDA-approved product labeling. This dissertation describes
a survey study designed to address how the variability in substance abuse terminology,
specifically package inserts, affects the prescribing decisions made by physicians.

xiii

A random sample of 1008 physicians currently licensed and residing in the
Commonwealth of Virginia received a letter of explanation, a self-administered
questionnaire, and a follow-up reminder and thank you. To increase response rate, a
second questionnaire was sent to non-responders. Prescribing decisions made by
physicians were measured as three variables: comfort level with a prior physician’s
choice, likelihood of refilling the prescription, and likelihood of prescribing a drug or
drug class as the first physician seeing a particular patient. Physicians were presented
with four case scenarios which included package insert information and selected patient
characteristics. Other factors affecting physicians’ decisions in prescribing controlled
substances include ideas about addiction, and characteristics of the physician, patient,
disease state, and drug. The patient case scenarios and other items on the questionnaire
addressed these covariates.
Based on the number of deliverable questionnaires returned and included in
analysis, the response rate was 32.3%. More physicians associated abuse, craving, drugseeking behavior, psychological dependence, and withdrawal with addiction than with
drug dependence, while more physicians felt that physical dependence and tolerance were
necessary for drug dependence. The most frequently used sources for drug information
were the Physicians’ Desk Reference (PDR), package inserts, and pharmacists.

xiv

Four linear regression models were created for physician prescribing decisions.
Physician, patient and package insert characteristics were all significant (p<0.05).
Interaction terms for type of pain and history of substance abuse were also significant,
indicating that the importance of substance abuse history is dependent on the type of pain
being treated.
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Introduction

CHAPTER 1
Introduction

Overview of the Document
This dissertation describes a survey research study designed to investigate how
the variability in substance abuse and dependence terminology in package inserts affects
prescribing decisions made by physicians, explore how physicians define “drug
dependence” and “drug addiction,” and identify the sources used by physicians for drug
information. This chapter provides background information on prescription drug abuse in
the United States, the history of substance abuse and dependence terminology, and
factors affecting physician prescribing decisions. Chapter 2 presents a more in depth
overview of the literature of terminology, package inserts, and physician surveys.
Chapter 3 provides details on a preliminary study of package insert information
specifically on substance abuse and dependence information. Chapter 4 describes the
methodology used for this survey study, Chapter 5 portrays its results, and Chapter 6
summarizes and discusses conclusions from the study.

Prescription Drug Abuse in the United States
Dr. Alan Leshner, the Director at the National Institute on Drug Abuse (NIDA),
stated in a July 2001 research report that “abuse of prescription drugs remains a serious
public health concern.” (National Institute of Drug Abuse (NIDA), 2001).
1

2
Looking specifically at non-medical use of prescription drugs, four categories are
examined by the National Survey on Drug Use and Health (NSDUH). They are: pain
relievers, stimulants, tranquilizers, and sedatives. Non-medical use is classified as intake
of a prescription medication that is not prescribed for the person using it or use only for
the feeling that is caused by the drug. Table 1.1 shows, for 1990 and 2001, the number of
people using these four categories of prescription drugs for non-medical use.

Table 1.1 New non-medical users of prescription drugs

Category
Pain relievers
Stimulants
Tranquilizers
Sedatives

1990
628,000
270,000
373,000
<300,000

2001
2,400,000
808,000
1,100,000
<300,000

There is a notable increase in initiation of use of prescription pain relievers,
stimulants, and tranquilizers over the 11 years spanning 1990 and 2001. The number of
sedative initiates, however, has remained under 300,000 since 1981. Peak use of
sedatives was at 638,000 new users in 1977, then steadily dropped off and remained
fairly stable, with a slow but steady rise from 111,000 in 1995 to 175,000 in 2000 (OAS,
2003). Clearly, while sedatives have not proven to be as popular for new users,
tranquilizers, stimulants, and prescription pain relievers have shown large increases in the
estimated number of new users over the 11 years spanning 1990 to 2001.
From 2002 to 2004, first time non-medical use of pain relievers remained steady
at about 2.4 million, tranquilizers at about 1.2 million, stimulants remained in the
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700,000’s, and sedatives continue to remain under 300,000. Data collected before 2002
cannot be compared to data collected after 2002 because of methodology changes,
making trend analysis for recent years unreliable. Several more years of data are needed
to determine whether any trend is present.
Overall, lifetime non-medical use of psychotherapeutics increased significantly
from 32.4 million to 36.0 million from 2000 to 2001 (p<0.01) (OAS, 2001). The increase
in past-year prevalence, from 3.9% (8.76 million) to 4.9% (11.10 million), and the
increase in past-month prevalence, from 1.7% (3.85 million) to 2.1% (4.81 million) was
also significant (p<0.01) (OAS 2001). From 2002 to 2004, lifetime non-medical use of
psychotherapeutics increased from 46.8 million to 48.0 million, and lifetime non-medical
use of pain relievers increased from 29.6 to 31.8 million users (p<0.05) (OAS, 2004).
Past-year prevalence has remained steady at about 14.6 million users, or about 6.2% of
the population (OAS, 2004). Past-month prevalence, a measure of current use, has also
remained steady, at about 6 million or 2.5% of the population (OAS, 2004).
Some may argue that drugs like heroin pose a much larger problem than abuse of
prescription drugs. On January 21, 2005, the Substance Abuse and Mental Health
Services Administration (SAMHSA) released a new report based on data collected from
the NSDUH in 2002 and 2003. This report was comparing non-medical use of
oxycodone to heroin use. From 2002 to 2003, the prevalence of lifetime non-medical use
of oxycodone increased from 11.8 million to 13.7 million users, from 5.0 to 5.8%.
Heroin use, however, remained steady at 1.6% prevalence of lifetime use (OAS 2005).
This suggests that people may be turning to prescription drugs as an alternative to illicit
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drug use, although further data are needed to determine whether or not this is an
incidental phenomenon or a trend over time. Further evidence supporting this theory was
reported in a recent publication from NIDA, stating that while the abuse of some drugs
such as LSD (lysergic acid diethylamide) and Ecstasy fell, the lifetime abuse of
prescription medications, particularly narcotic painkillers, has significantly increased
from 2002 to 2003. The young adult age group (18-25 years) showed a 15% increase in
lifetime and past-month non-medical use of pain relievers (OAS, 2004).
Whether or not the increasing trends in the prevalence and incidence of new use
of prescription drugs for non-medical use reflects abuse of drugs depends on how
“abuse” is defined. If any use of a substance specifically for the feeling it causes and not
for a prescribed indication is considered abuse, then the above statistics suggest an
increase in abuse. If a diagnosis of a substance abuse or dependence disorder is required,
a different set of reports must be examined.
The July 2004 Drug and Alcohol Services Information System (DASIS) report
points out that between the years of 1992 and 2002, the rate of admission for treatment
for the abuse of narcotic painkillers more than doubled (OAS 2004). The total number of
treatment admissions between 1997 and 2002 increased by 17%; however, the number of
admissions for primary abuse of narcotic painkillers rose 186%, while treatment
admissions for heroin abuse increased by 21% (OAS 2004). This is strongly indicative of
an increase in prescription drug abuse, specifically that of narcotic painkillers.
Both the non-medical use of prescription drugs and treatment admission rates for
prescription drug abuse have been on the rise, particularly in the last 5–10 years. These
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trends unmistakably convey that prescription drug abuse in the United States is a public
health problem.

Terminology of Substance Abuse and Dependence
The definitions of addiction, abuse, and dependence have been debated by
scientists and researchers for decades. Numerous review and opinion papers propose
definitions and appropriate use of the words. In 2001, the American Academy of Pain
Medicine, the American Pain Society, and the American Society of Addiction Medicine
formed the Liaison Committee on Pain and Addiction (LCPA), and developed working
definitions of “addiction, physical dependence, and tolerance” and recommended their
use (Savage, Joranson, Covington, Schnoll, Heit, Gilson 2003). Addiction was defined as
“a primary, chronic, neurobiologic disease, with genetic, psychosocial, and
environmental factors influencing its development and manifestations. It is characterized
by behaviors that include one or more of the following: impaired control over drug use,
compulsive use, continued use despite harm, and craving.” (Savage et al 2003). Physical
dependence was defined as “a state of adaptation that is manifested by a drug class
specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose
reduction, decreasing blood level of the drug, and/or administration of an
antagonist.”(Savage et al 2003). Tolerance was defined as “a state of adaptation in which
exposure to a drug induces changes that result in a diminution of one or more of the
drug's effects over time.” (Savage et al 2003). The LCPA has not yet provided
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definitions for “psychic or psychological dependence,” and “abuse,” two other terms of
interest in this study.
Two NIDA websites refer to the Diagnostic and Statistical Manual of Mental
Disorders, 3rd and 4th editions (DSM-III-R and DSM-IV) for criteria-based definitions of
substance abuse and dependence and offer working definitions of “psychoactive
substance use,” “psychoactive substance abuse (or problematic use),” and “addiction.”
(available at http://165.112.78.61/Diagnosis-Treatment/Diagnosis2.html,
http://www.nida.nih.gov/Drugpages/DSR.html). One website indicates that “drugs may
be used in a socially accepted or medically sanctioned manner to modify mood or state of
mind.” Having a drink with a friend or taking anxiolytic agents for anxiety as directed by
a physician is classified as psychoactive substance use. “Psychoactive substance abuse or
problematic use” is defined as “the use of a substance…in a manner that is illegal or
harmful to oneself.” A distinct definition of “addiction” is not given, although the
website describes it as being “characterized by the repeated, compulsive seeking or use of
a substance despite adverse social, psychologic and/or physical consequences” (available
at http://www.nida.nih.gov/Drugpages/DSR.html).
Ferrell and colleagues performed a qualitative assessment of information in
fourteen textbooks about opioid use and addiction potential. They found that
information, based on the researchers’ definition of “addiction,” was more often
inaccurate than not, and highly varied in how “addiction” was defined and used (Ferrell,
McCaffery, and Rhiner, 1992).
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In a survey of 500 physicians, researchers gathered data about general knowledge
of practitioners in the area of pain management, including the definition of “addiction”
and legal issues associated with prescribing controlled substances. Addiction was
defined in a variety of ways by survey respondents, even when it was presented as a
multiple choice question (Greenwald, Narcessian, and Pomeranz, 1999).
The Federal Controlled Substances Act of 1970 also uses the word “addiction,”
stating that an addict is one “who is so far addicted to the use of narcotic drugs as to have
lost power of self-control with reference to his addiction” (available at
http://www.usdoj.gov/dea/agency/csa.htm). The Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, text revision (DSM-IV-TR) does not use the word
“addiction,” but instead gives criteria for “substance abuse” and “substance dependence,”
respectively (American Psychiatric Association (APA), 2000). Clearly, there is a lack of
consensus of the definition and use of the language of substance abuse and dependence.

Factors Affecting Physicians’ Prescribing Decisions
A survey study by Potter et al in 2001 determined that a low level of concern
about physical dependence, tolerance, and addiction was the most significant predictor of
the willingness of a physician to prescribe opioids to patients with chronic non-malignant
pain. The year of graduation from medical school was found to be significant in two
models at p-values of 0.0025 and 0.0048 (Potter, Schafer, Gonzalez-Mendez, Gjeltema,
Lopez, Wu et al., 2001). Specifically, more recent graduation from medical school
increased willingness to prescribe under the conditions of the models. Additionally,
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concern about regulatory scrutiny was significant (p=0.0424), with fear of regulatory
scrutiny limiting the willingness to prescribe opioids (Potter et al., 2001).
In a 1994 study of physicians conducted by Turk and colleagues, 1912 of 6962
physicians (response rate 27.46%) returned a questionnaire with items regarding years of
practice, frequency of long-term treatment with opioids, number of chronic pain patients
treated, and concerns about regulatory pressure, among other variables. The purpose of
this study was to assess the attitudes and practices of physicians with regard to long-term
prescribing of opioids for non-cancer pain. There was a significant difference found in
the frequency of prescribing opioids long-term among the specialties (ANOVA p<0.001).
Rheumatologists were significantly more likely to prescribe opioids long-term than any
other specialty (p<0.003) (Turk, Brody, Okifuji, 1994). This suggests that specialty is a
predictor of physician prescribing decisions but provides no information on the
significance or amount of the variance explained in physician prescribing decisions.
Weinstein and colleagues from the University of Texas also conducted a survey
about the use of opioid analgesics. A 59-item questionnaire was employed to identify
how physicians’ attitudes and knowledge contribute to pain management practices. Four
scales were identified: reluctance to prescribe opioids, fear of patient addiction, tolerance,
or dependence, fear of regulatory agency scrutiny, and knowledge about pain and its
treatment. Correlating the fear of regulatory scrutiny scale with medical discipline
revealed that internists had decreased fear compared to anesthesiologists/surgeons, but
this difference was not statistically significant (Weinstein, Laux, Thornby, Lorimor, Hill,
Thorpe, and Merrill, 2000).
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Another survey examining prescription decisions used a series of 24 patient cases
to measure physician prescribing of benzodiazepines while varying four factors. These
four factors were health status, psychiatric diagnosis, stability of job and marriage, and
short-term ability to work. Psychiatric diagnosis and the health status of an alcoholrelated medical problem were found to be significant predictors of agreement to prescribe
benzodiazepines. Added to the regression model were physician characteristics of year
of graduation from medical school and specialty, among others. This study did not find
the physician characteristics to be significant with regard to physician prescribing
decisions (Brown, Brown, Saunders, Castelaz, and Papasouliotis, 1997).
A survey of emergency department physicians also used vignettes to identify
factors influencing prescribing decisions. One of the specific aims of this project was to
“determine whether physicians’ characteristics are associated with either their baseline
likelihood of opioid prescribing or their responses to additional information.” Year of
graduation from medical school and specialty were among the variables included in
physician characteristics examined. This study did not find any significance in any
physician characteristics with regard to prescribing of opioid medications (TamayoSarver, Dawson, Hines, Cydulka, Wigdon, Albert, Ibrahim, Baker, 2004).
In summary, factors found to influence physician prescribing decisions
include concern about dependence, length of physician practice, diagnosis, fear of
regulatory scrutiny, and physician specialty. Other factors found to affect physician
prescribing decisions include: potency of drug prescribed, indication for which drug is
prescribed, patient's history of drug abuse, familiarity with guidelines, medical discipline

10
or specialty, and age of physician (Schumock, Walton, Park, Nutescu, Blackburn, Finley,
and Lewis, 2004; Davies and Huxley, 1997).

Problem Statement
The review of the literature surrounding substance abuse and dependence
terminology prompted a preliminary exploration of package inserts, an important source
of information for prescribers. The use of terminology and amount of information in the
sample of package inserts studied was found to be highly varied, with no predictable
patterns across classes or controlled substance schedules (Phipps, Balster, Slattum, and
Kirkwood, in press). Education of health care providers using materials with nonstandardized terminology and varied information about substance abuse and addiction
could lead to variability in physician understanding. This could affect decisions that
physicians make about prescribing medications, which could affect the quality of
substance abuse treatment and social aspects of substance abuse research.

Significance
This study aims to increase knowledge about how physicians interpret
terminology associated with substance abuse and dependence information in package
inserts and to characterize how this variability affects prescribing decisions made by
physicians. The information generated in this study can be used as groundwork for
additional studies in the communication of information to physicians and the
development and evaluation of clearer, more useful package inserts.
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Objectives
Prescription drug abuse is an on-going problem in the United States. Educating
health care providers about substance abuse issues is an important factor in both the
prevention and treatment of prescription drug abuse. Package inserts are an important
source of drug information for health care providers, and variability in substance abuserelated terminology use in package inserts is high (Phipps et al, in press). Using survey
research methods, this project aims to:
1) Describe how physicians define the terms drug dependence and addiction
2) Characterize sources used by physicians for drug abuse and dependence and other
drug information
3) Portray the scope of the problem of varied terminology in package inserts by
characterizing its effects on physician prescribing decisions when modeled with
covariates of physician and patient characteristics
4) Provide groundwork for research designed to evaluate and develop more useful
package inserts.

Summary
Review of literature has revealed a lack of consensus of the language surrounding
the public health problem of substance abuse and dependence. This project is intended to
elucidate how this variability affects prescribing decisions made by physicians.

2

Literature Review

CHAPTER 2
Literature Review

Overview
This chapter offers a more in-depth review of the literature summarized in
Chapter 1 and provides support for the variables included in the survey study.

Prescription Drug Abuse in the United States
The National Survey on Drug Use and Health (NSDUH), formerly known as the
National Household Survey on Drug Abuse (NHSDA), is funded by the Substance Abuse
and Mental Health Services Administration (SAMHSA). SAMHSA is an agency under
the United States Department of Health and Human Services (DHHS). Periodically,
SMHSA’s Office of Applied Studies (OAS) publishes its findings in a series of reports.
These reports provide information about the prevalence and incidence of drug use in the
United States.
As stated in the Introduction, NSDUH reports have shown an increase in both
incidence and prevalence of non-medical use of prescription drugs over the 11 years
spanning 1990 and 2001. The four classes of prescription drugs included in the NSDUH
are pain relievers, stimulants, tranquilizers, and sedatives. Non-medical use is defined as
“use of prescription-type drugs not prescribed for the respondent by a physician or used
only for the experience of feeling they caused.”
12
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A sample of households in the U.S. is randomly selected, and each is personally
visited by an interviewer, who obtains consent and administers the questionnaire. Most
of the questionnaire is self-administered on a computer, with a few questions asked and
entered by the interviewer.
It is important to note that several changes in methodology and analysis occurred
in 2002, making it difficult to compare data collected before 2002 to data collected from
2002 onward. One of the changes in methodology that occurred in 2002 is the name
change of the survey from National Household Survey on Drug Abuse to the National
Survey on Drug Use and Health. Because of the problem of social desirability in survey
research, the current name could have had an impact on response rate, particularly those
who do not use drugs recreationally, as they may be less likely to participate in a survey
on “drug abuse” than on “drug use and health.” A second change in methodology is the
addition of a $30 incentive for participants, which could also affect response rate in the
general population. In fact, the response rate increased from ~73% in 2000 to ~78% in
2002, and has remained at about 78% for 2003 and 2004 (NHSDA 2000 and NSDUH
2004). Other changes have included techniques employed for weighting the samples,
wording and addition of questions, and format of the informational brochure given to
respondents.
Chapter 1 of this document illustrated the escalation in incidence of prescription
drug categories from 1990 to 2001. New non-medical use of pain relievers proved the
largest increase, from 628,000 in 1990 to 2.4 million in 2001 (Office of Applied Studies
(OAS), 2003). For the same years, new users of stimulants rose from 270,000 to 808,000
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and tranquilizer initiation soared from 373,000 to 1.1 million. New use of sedatives,
however, has remained under 300,000 new users since 1981. Initiation of sedatives
peaked at 638,000 in 1977, then steadily dropped off and remained fairly stable. While
the number of new users of sedatives has remained under 300,000, it has recently begun a
slow but steady rise, from 111,000 in 1995 to 175,000 in 2000 (OAS, 2003). Clearly,
while sedatives have not proven to be as popular for new users, tranquilizers, stimulants,
and especially prescription pain relievers have shown large increases in the estimated
incidence of new use over the 11 years spanning 1990 to 2001. It is interesting to note
that there seems to be an actual decrease in new use of these three categories of drugs
from 2000 to 2001. Pain reliever initiation dropped from 2.7 to 2.4 million, tranquilizers
from 1.3 to 1.1million, and stimulants from 983,000 to 808,000 (Office of Applied
Studies, 2003). Because of the aforementioned methodology changes of 2002, however,
data collected beyond this point cannot be used to determine whether or not this is the
beginning of a downward trend.
In recent years, new use of prescription drugs for non-medical purposes seems to
have stabilized. From 2002 to 2004, first time non-medical use of pain relievers lingered
at ~2.4 million, tranquilizers at ~1.2 million, stimulants steadied in the 700,000’s, and
sedatives continue to remain under 300,000. (https://nsduhweb.rti.org/). As stated
previously, however, because of the methodology changes of 2002, data collected before
2002 cannot be compared to data collected after 2002, making trend analysis for recent
years unreliable. Several more years of data are needed to determine whether any trend is
present, with 2002 data serving as a new baseline.
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In addition to incidence, or new use of prescription drugs, SAMHSA gathers
information on lifetime prevalence and estimates past-year and past-month prevalence.
From 2000 to 2001, lifetime non-medical use of prescription drugs significantly rose
from 32.4 million to 36.0 million (p<0.01) (OAS, 2001). Also significant at the p<0.01
level are the increases in past-year prevalence, from 3.9% (8.76 million) to 4.9% (11.10
million), and past-month prevalence, from 1.7% (3.85 million) to 2.1% (4.81 million)
(OAS 2001). Past-month prevalence is indicative of current use.
From 2002 to 2004, overall lifetime non-medical use of psychotherapeutics has
increased from 46.8 million to 48.0 million (http://oas.samhsa.gov/nhsda.htm). Again, it
is important to mention that a conclusion cannot be drawn about the apparent increase
from 36.0 million in 2001 to 46.8 million in 2002. Past-year prevalence has remained
steady at about 14.6 million users, or about 6.2% of the population, as has past-month
prevalence, at about 6 million or 2.5% of the population
(http://oas.samhsa.gov/nhsda.htm).
In 2002, the prevalence of non-medical pain reliever use in the U.S. was estimated
at 13%, or almost 30 million people aged 12 or older (Office of Applied Studies, 2004).
Males were more likely than females to have used a prescription pain reliever nonmedically (14.3 vs. 11.0%) in their lifetime, and Caucasians were more likely than other
race/ethnicities (White: 13.6%, Black: 9.7%, Asian: 7.0%, Hispanic: 11.0%).
It is interesting to note that with regard to specific substances, tramadol, a noncontrolled pain reliever available only by prescription, was used nonmedically by
approximately 1 million people, which is similar to the estimated use of methadone (0.9
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million) and Dilaudid® (1.1 million) (Office of Applied Studies, 2004). OxyContin®
and morphine users were at 1.9 and 2.1 million, respectively. The most highly used pain
relievers were found to be propoxyphene containing (Darvocet® and Darvon®), and
Tylenol® with codeine, at 18.9 million, followed by hydrocodone products (Vicodin®,
Lortab®, and Lorcet®) at 13.1 million (OAS, 2004). Codeine products weighed in at 6.9
million users.
Looking at the data collected from 2002 to 2004, lifetime non-medical use of pain
relievers has increased from 29.6 to 31.8 million users (p<0.05). Again, propoxyphene
containing products remained the most commonly used pain relievers at 9.0%, followed
by hydrocodone and then oxycodone containing products at 7.9% and 4.9%, respectively.
Tramadol containing products were estimated as being used by 0.5% of the population
(http://oas.samhsa.gov/nhsda.htm).
While in the youth age group (12 – 17 years), lifetime non-medical pain reliever
use prevalence seems to have risen from 2001 to 2002 (9.6 to 11.2%) and non-medical
stimulant use prevalence from 3.8 to 4.3%, it is difficult to interpret this phenomenon
because of the previously mentioned changes in measurement methodology from 2001 to
2002. In recent years, however, the overall prevalence of lifetime non-medical use of
pain relievers in youths aged 12-17 years has remained fairly constant, at 11.2% in 2002
and 11.4% in 2004. However, the non-medical use of Oxycontin® has increased in
prevalence from 0.9 to 1.2% (p<0.05). Lifetime use of stimulants has decreased in
prevalence from 4.3% to 3.4% (p<0.01), and prevalence for tranquilizers and sedatives
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has remained constant at about 3.3% and 1.0%, respectively
(http://oas.samhsa.gov/nhsda.htm).
Some may argue that illicit drugs like heroin pose a much larger problem than
abuse of prescription drugs. On January 21, 2005, SAMHSA released a new report based
on data collected from the NSDUH in 2002 and 2003. This report was comparing nonmedical use of oxycodone to heroin use. From 2002 to 2003, the prevalence of lifetime
non-medical use of oxycodone increased from 11.8 million to 13.7 million users, from
5.0 to 5.8%. Heroin use, however, remained steady at 1.6% prevalence of lifetime use
(OAS 2005). Therefore, not only is the prevalence for oxycodone higher than that of
heroin to begin with, it is also increasing. This might suggest that people are turning to
prescription drugs as an alternative to illicit drug use, although further data are needed to
determine whether or not this is an incidental phenomenon or a trend over time. Further
evidence supporting this theory was reported in a recent publication from NIDA, noting
from the NSDUH 2003 survey that while the abuse of some drugs such as LSD and
Ecstasy fell, the lifetime abuse of prescription medications, particularly narcotic
painkillers, significantly increased from 2002 to 2003, with the young adult age group
(18-25 years) showing a 15% increase in lifetime and past-month nonmedical use of pain
relievers (NIDA 2004, OAS 2004).
The Drug and Alcohol Services Information System (DASIS) report is a source of
information on substance abuse treatment services. Like the NSDUH report, it is
published periodically by the Office of Applied Studies at SAMHSA. As mentioned in
the introductory chapter, the July 23, 2004 report indicates that between the years of 1992
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and 2002, the rate of admission for treatment for the abuse of narcotic painkillers has
more than doubled (OAS 2004). The total number of treatment admissions between 1997
and 2002 increased by 17%; however, the number of admissions for primary abuse of
narcotic painkillers rose 186%, while treatment admissions for heroin abuse increased by
21% (OAS 2004). This further underscores the problem associated with abuse of
prescription drugs, particularly pain medications.
This report also reports admission rates by state, as number of admissions per
100,000, in categories of <14, 14-18, 19-23, or ≥24. There is a trend upward in the
number of states that have reached the category of ≥24/100,000. Specifically, the number
of states reporting admission rates of ≥24/100,000 has increased from 5 in 1992, to 11 in
1997, to 31 states in 2002 (OAS 2004). Notably, the highest rates were in Maine and
Connecticut (207 and 89 per 100,000, respectively). This perhaps suggests a need for a
shift in the scale of how admission numbers are categorized. A promising trend noted is
that the median duration of use before first seeking treatment has decreased. In 1992,
people abused drugs for a median of 9 years before first seeking treatment, and this has
decreased to 7 years in 1997, and further decreased to 4 years in 2002 (OAS 2004).
While this indicates that people are getting treatment faster, this may also mean an
increase in the need for resources for treating substance abusers of prescription drugs.
Both the non-medical use of prescription drugs and treatment admission rates for
prescription drug abuse have been on the rise, particularly in the last 5–10 years. These
trends clearly demonstrate that prescription drug abuse in the United States is a public
health problem.
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Terminology Variability
As mentioned in the introductory chapter, there are currently many different
views on the definition of “addiction.” Numerous committees and organizations have
proposed appropriate definitions and use for the term. Some of these have included: the
American Psychiatric Association, the National Institute on Drug Abuse, and the Liaison
Committee on Pain and Addiction (LCPA) formed by the American Academy of Pain
Medicine.
LCPA defined addiction as “a primary, chronic, neurobiologic disease, with
genetic, psychosocial, and environmental factors influencing its development and
manifestations. It is characterized by behaviors that include one or more of the following:
impaired control over drug use, compulsive use, continued use despite harm, and
craving.”
Two NIDA websites refer to the Diagnostic and Statistical Manual of Mental
Disorders, 3rd and 4th editions (DSM-III-R and DSM-IV) for criteria-based definitions of
substance abuse and dependence and offer working definitions of “psychoactive
substance use,” “psychoactive substance abuse (or problematic use),” and “addiction”
(http://165.112.78.61/Diagnosis-Treatment/Diagnosis2.html,
http://www.nida.nih.gov/Drugpages/DSR.html). One website indicates that “drugs may
be used in a socially accepted or medically sanctioned manner to modify mood or state of
mind.” This is classified as psychoactive substance use, and gives the examples of
having a drink with a friend and taking anxiolytic agents for anxiety as directed by a
physician. “Psychoactive substance abuse or problematic use” is defined as “the use of a

20
substance…in a manner that is illegal or harmful to oneself.” A distinct definition
“addiction” is not given, although the website describes it as being “characterized by the
repeated, compulsive seeking or use of a substance despite adverse social, psychologic
and/or physical consequences” (http://www.nida.nih.gov/Drugpages/DSR.html).
The Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text
revision (DSM-IV-TR) does not use the word “addiction,” but instead gives criteria for
“substance abuse” and “substance dependence,” respectively (American Psychiatric
Association, 2000).
While no studies specifically addressing substance abuse terminology in package
inserts were found, textbook content has been previously examined. A qualitative
assessment of information about opioid use and addiction potential in fourteen textbooks
was performed by Ferrell, McCaffery, and Rhiner (1992). Of the fourteen texts
examined, eight were pharmacology and six were medical/surgical textbooks.
Information was assessed based on two questions:
1) Is addiction defined as psychological dependence and distinguished from
tolerance and physical dependence in accordance with current definitions used by
the American Pain Society (APS) and the World Health Organization (WHO)?
2) Is the incidence of addiction accurately stated?

The researchers do not specifically state a definition of addiction that was used as
criteria, but in the introduction, they state that addiction is “a psychological and
behavioral syndrome characterized by overwhelming involvement with obtaining and
using the drug for effects other than pain relief” (Ferrell, et al, 1992). They assert that
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only one of the fourteen textbooks used the correct definition of addiction, and that
frequently, textbooks used the term “dependence” without specifying physical or
psychological. A few of the statements found in the textbooks evaluated are as follows
(Ferrell, et al, 1992):
•

“Addiction and psychological dependence are defined as separate entities.”

•

“Addiction is a process of physiological dependence which is characterized by the
two primary components of tolerance and withdrawal syndrome.”

•

“All narcotics created psychologic and physical dependence and tolerance…”

A textbook outlining symptoms of morphine abuse included constipation and withdrawal
symptoms on the list. The same textbook that was deemed to have the correct definition
of addiction was also the only one to also correctly state that the incidence of iatrogenic
addiction to opioids when used for medical reasons is less than 1% (Ferrell, et al, 1992).
While this study is highly subjective and detailed information about how the qualitative
evaluation took place, the results of this study suggest that there is variability in the
information used in the didactic training of students entering the health care profession.
It did not address drug information resources used by current practitioners.
It stands to reason, then that health care professionals exposed to the variety of
sources available to them might differ in how they perceive the term “addiction.”
Greenwald et al conducted a survey of 500 physiatrists in the United States, randomly
selected from the list of members of the American Academy of Physical Medicine and
Rehabilitation (AAPMR). Each of the selected physicians received a cover letter, a
questionnaire, and stamped return envelope. Non-responders received a second packet

22
three weeks later. A response rate of 50.6% complete enough for analysis was achieved
(Greenwald, Narcessian, Pomeranz, 1999). Questionnaire items addressed the types of
patients treated, drugs the physicians were willing to prescribe for cancer and non-cancer
pain, pharmacologic and legal aspects of opioid use, and the definition of “addiction.”
Demographic information gathered included the physicians’ age, state, and the year of
medical school completion.
The definition of “addiction” was asked as a multiple choice question. Physicians
were asked to choose one or more of the following: physical dependence, tolerance,
and/or psychological dependence. An answer of “don’t know” was also an option. Table
2.1 shows the respondents’ answers.

Table 2.1 Definitions of addiction*

Terms chosen
% respondents
Physical dependence, tolerance,
27
and psychological dependence
Physical dependence and tolerance
2
Psychological dependence and tolerance
2
Physical and psychological dependence
26
Physical dependence
14
Psychological dependence
25
Don’t know
3
*Data compiled from Greenwald et al 1999

This finding supports the idea that physicians have varying views on what addiction
means.
A true/false item on the questionnaire revealed that 14.4% of respondents either
thought that a patient would become addicted to opioids if used daily for one month
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regardless of diagnosis (8.1%), or did not know (6.3%). This could reflect a
misconception of the incidence of iatrogenic addiction to opioids used for legitimate
medical purposes; however, it could also be that the respondents differed in their
perceptions of “addiction.” Based on the results shown in Table 2.1, only 25% of
respondents defined “addiction” as “psychological dependence,” which is what the
researchers considered a correct answer (Greenwald et al, 1999).
The sampling frame chosen in this study limits the generalizability of results to
members of the AAPMR, and only about 50% of physiatrists in the U.S. are members
(Greenwald et al, 1999). It is possible that physiatrists in the U.S. who are not members
of AAPMR would answer differently from the respondents. Even within the AAPMR
sample, there was a difference noted in that 8.4% of respondents belonged to the
AAPMR Pain Special Interest Group, but only 4.3% of AAPMR members overall belong
to this group (Greenwald et al, 1999). Additionally, because this study focused on
specialists in physical medicine and rehabilitation, no conclusions can be drawn about
possible opinions of physicians in other specialties.

Factors Affecting Physicians’ Prescribing Decisions
Many studies have aimed at identifying factors that affect decisions that
physicians make when prescribing medications. Several of them will be discussed in this
section.
In a 1994 study of physicians conducted by Turk, Brody, and Okifuji, 1,912 of
6,962 physicians (response rate 27.46%) returned a questionnaire with items regarding
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years of practice, frequency of long-term treatment with opioids, number of chronic pain
patients treated, and concerns about regulatory pressure, among other variables (Turk, et
al 1994). The stated purpose of this study was to assess the attitudes and practices of
physicians with regard to long-term prescribing of opioids for non-cancer pain (Turk, et
al 1994). Upon further examination of the methods and analysis, it appears that there was
a particular interest in physician specialty and region of practice in the United States.
Each of the aforementioned variables was analyzed by ANOVA against physician
specialty and region of practice. There were 5 regions of practice: Northeast, Midwest,
Southeast, Southwest, and Pacific. Four specialty areas were identified from seven
originally chosen. Those four were: general practice, surgery, rheumatology, and
neurology/physiatry. General practice was made up of family practice and internal
medicine specialties, while surgery contained neurosurgeons and orthopedic surgeons.
Additionally, neurologists and physiatrists were combined into a single group, called
NPM. The sample was a stratified, random sample of physicians in the United States. A
random sample of physicians from two states in each of the five regions was chosen to
receive a questionnaire.
Frequency of prescribing opioids was measured on a 7-point Likert scale where 0
indicated “never” and 6 was defined as “very frequently.” There was a significant
difference found in the frequency of prescribing opioids long-term among the specialties
(ANOVA p<0.001) (Turk, et al, 1994). Not surprisingly, rheumatologists were found to
prescribe long-term opioids more frequently than any other specialty (mean=1.98,
SD=1.45), with surgeons reporting the least frequent prescribing of opioids for persistent
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pain (mean=1.14, SD=1.31) (Turk, et al, 1994). The use of parametric statistics for this
analysis is questionable. While the sample size was very large and a 7-point Likert scale
is often treated as continuous data, the results for the surgery group, specifically a
standard deviation greater than the mean, imply that a negative answer was possible,
which it was not. Therefore, these results must be interpreted with some caution. It is
unknown whether or not Kruskal-Wallis, the non-parametric analogue to ANOVA, would
have shown statistical significance. It is also interesting to note the wording of this item
on the questionnaire: “How frequently do you prescribe chronic (maintenance) opioids
for persistent pain?” While the other items on the questionnaire specify and even stress
non-cancer pain in italics, this item indicates only “persistent” pain and could have been
interpreted differently by some physicians.
Other items on the questionnaire addressed concerns about addiction, tolerance,
and physical dependence. Because these items were found to be significantly correlated
(p<0.001), they were collapsed into a category designated as “concerns about ATD”
(Turk, et al, 1994). The mean score for the items was used as the ATD score. ANOVA
indicated that there was a significant difference in these scores among the specialties
(p<0.001) (Turk, et al, 1994). Again, the greatest difference was between
rheumatologists and surgeons, showing the least concern and the greatest concern,
respectively, although Tukey’s HSD test indicated that each group differed significantly
from the others (Turk, et al, 1994).
With respect to region of the country, frequency of prescribing differed
significantly (p<0.001), but concerns about ATD did not (Turk, et al, 1994). Physicians
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in the Midwest were less likely to prescribe maintenance opioids for persistent pain than
those in the Southeast or the West (Turk, et al, 1994). Additionally, physicians in states
where multiple prescriptions are required for CII medications demonstrated a
significantly lower frequency of prescribing than those states not requiring multiple
prescriptions (p<0.001) (Turk, et al, 1994). However, these data must also be interpreted
with caution, as there were only three out of the ten states chosen that required multiple
prescriptions, indicating the likelihood that the sample sizes were not equal in the groups,
as is assumed in ANOVA. Furthermore, the degrees of freedom for the ANOVA were
reported as 1 and 1,225 (Turk, et al, 1994). With a returned sample size of 1,912, this is
indicative of a large amount of missing data for this question.
The results of this study suggest that practice specialty is a predictor of physician
prescribing decisions but provides no information on the significance or amount of the
variance explained in physician prescribing decisions.
In 2001, Potter and colleagues conducted a survey of primary care physicians who
were part of the University of California, San Francisco/Stanford Collaborative Research
Network (CRN). Any member of the network who was not involved with the study was
chosen to receive a questionnaire, resulting in a sample size of 230 (Potter et al, 2001).
Multiple contacts, including 2 mailed reminders and up to 3 phone calls, were used to
increase response rate. The questionnaire was made up of 3 patient case scenarios with
follow-up questions, items related to attitudes about opioids and prescribing decisions,
and demographics. The purpose of the study was to gain insight into physicians’
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attitudes toward the use of opioids in chronic, non-malignant pain (CNMP) and factors
affecting willingness to prescribe opioids.
The dependent variable, willingness to prescribe opioids, was measured in three
ways. First, a sum scale was created from answers to the follow-up question from the
vignettes: “If the pain persisted unchanged, would you prescribe opioids for this patient
on a long-term basis?” The second model was measured as level of agreement with a
statement about prescribing CIII medications on an as-needed basis for CNMP, and the
third model for CII medications on a scheduled basis for CNMP.
Independent variables included patient variables, which were included in the
vignettes, and physician demographics. There were 2 significant predictors for the first
model and three each for the second and third models. Lower level of concern about
physical dependence was a significant predictor of willingness to prescribe opioids in all
three models, with R2 values of 0.21 (p=0.0001), 0.07 (p=0.0011), and 0.15 (p=0.0001),
respectively (Potter et al, 2001). Originally, the researchers had also inquired about level
of concern about tolerance and addiction and found these to be highly correlated with
each other and with level of concern about physical dependence. Because of this, the
variables for concern about tolerance and addiction were dropped. Therefore, it is
assumed that lower level of concern about physical dependence also indicates a lower
level of concern about addiction.
More recent graduation from medical school was significant in Models 1 and 2,
with R2 values of 0.04 (p=0.0025) and 0.05 (p=0.0048), respectively (Potter et al, 2001).
Concern about regulatory scrutiny was significant for the second model, explaining 2%
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of the variance in willingness to prescribe medications not requiring triplicates on an asneeded basis (p=0.0424) (Potter et al, 2001). For the third model, the other two
significant predictors were enjoyment in working with chronic pain patients and lower
patient case load, with R2 values of 0.06 (p=0.0014) and 0.03 (p=0.0103), respectively
(Potter et al, 2001).
Additionally, 16% of the respondents indicated that they would never prescribe
opioids to someone with a history of substance abuse, 42% would never prescribe opioids
to someone currently abusing drugs (Potter et al, 2001). This, coupled with the
significant predictor of concern about physical dependence, suggests that a patient’s
history of substance abuse would affect physician prescribing decisions.
Only 2% indicated that they would never prescribe CIII medications on an asneeded basis, but 35% said they would never prescribe CII medications on a scheduled
basis for CNMP (Potter et al, 2001). There also seemed to be differences in willingness
to prescribe opioids based on diagnosis, but all of the diagnoses presented were CNMP,
and no indication of statistical significance was noted in the article. These findings
suggest that the level of control of a substance and diagnosis also affect physician
prescribing decisions.
One limitation of this study is the extremely narrow sampling frame used. While
the researchers obtained a high response rate of 70% (Potter et al, 2001), only physicians
in a small area were chosen to participate in the study, so the generalizability is limited to
primary care physicians in the CRN. This is very small number of primary care
physicians, as indicated by the sample size of 230, which was the entire population of the
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group except for those who were involved in the study itself. Another limitation is found
in the design of models 2 and 3. Each model was based on the answer to a single
question. Because the question varied on both the level of control of the substance and
the dose scheduling, it is impossible to tease out the individual effects that either of these
might have alone. Because this study was designed to gather information on prescribing
of opioids for CNMP, all of the diagnoses presented were types of CNMP. Although
statistical and practical significance of differences found in willingness to prescribe
opioids for these conditions was not addressed, the differences were there. If there are
differences among diagnoses for the same type of pain, then it is certainly logical to
assume that there would also be differences in prescribing decisions for different types of
pain being treated.
In the previously mentioned Greenwald survey study, researchers asked a series
of questions about the legality and acceptability of prescribing opioids long-term for
patients with cancer pain and chronic, non-malignant pain, with and without histories of
opioid abuse. For cancer pain, they found that the percentage of respondents finding
long-term prescriptions for opioids both lawful and generally acceptable medical practice
dropped from 95.4% to 73.8% if the patient had a history of opioid abuse. Likewise, this
percentage dropped from 36.9% to 10.5% for chronic, non-malignant pain without and
with a history of opioid abuse, respectively. This finding supports the hypothesis that a
patient’s history of substance abuse could affect prescribing decisions, even for cancer
pain.
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Weinstein and colleagues also conducted survey about the use of opioid
analgesics (Weinstein, Laux, Throndby, Lorimor, Hill, Thorpe, 2000). A 59-item
questionnaire was employed to identify how physicians’ attitudes and knowledge
contribute to pain management practices. Researchers aimed to explore how physician
specialty and community size affected practices, and to identify barriers to effective pain
management. Medical disciplines identified were psychiatry, internal medicine,
surgery/anesthesia, and other. A random sample of physicians practicing in various
regions of Texas was drawn from the Texas State Board of Medical Examiners’ database.
The specific survey methods are not described in detail except to say that there were two
mailings of the questionnaire. Three hundred eighty-six physicians responded
(Weinstein, et al, 2000). The response rate, however, remains unknown, as the number of
questionnaires mailed is not given.
Factor analysis revealed three scales identifying barriers to adequate pain
management:
1) Reluctance to prescribe opioids (11 items),
2) Fear of patient addiction, tolerance, or dependence (5 items),
3) Fear of regulatory agency scrutiny (9 items).

Other items measured knowledge about pain and its treatment (13 items), psychological
attributes (18 items), and bias about sex and age (5 items). The Likert scale used ranged
from 1=Strongly agree to 7=Strongly disagree, so that a low sum score on a scale was
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indicative of agreement. For example, a low score on the reluctance scale would indicate
that the physician has a high level of reluctance to prescribe opioids.
With regard to physician specialty, no significant differences were found for the
three barrier scales, although the authors state that results “approach significance”
(Weinstein, et al, 2000). According to the article, the trend is that psychiatrists appear to
have lower reluctance and lower fear of patient addiction than the other specialties, and
internists tend to have more fear of regulatory scrutiny while surgeons have less.
Statistical significance (p<0.05) was achieved on items relating to psychological
attributes; the article states that psychiatrists have a more open attitude than other
specialties. (Weinstein et al, 2000).
However, when looking at the mean scores, it appears that the results are opposite
of the conclusions drawn in the article. For example, the mean score on scale 1 for
psychiatrists was 2.81, while the mean score for surgeons was 3.20. Because the scale
was defined as 1=Strongly agree and 7=Strongly disagree, this would imply that a lower
score indicates agreement with the items. Examining the items on scale 1, only one of
them would be reverse-scored. This item was worded “It is appropriate to escalate a dose
of narcotics above the usual range if the prognosis is less than 1 year” (Weinstein, et al,
2000). Agreement with other items on this scale appears to indicate higher reluctance.
For example, an item is phrased “Narcotics should be restricted to treatment of severe
intractable pain” (Weinstein, et al, 2000). Another item is worded “Persons who fit the
‘profile’ of a likely drug abuser should never be treated with narcotics” (Weinstein, et al,
2000). Based on the scale defined by the researchers, agreement with these items would
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result in a low score, not a high one. Careful examination of the items on the other scales
implies the same. The specific interpretations of results in this article, then, are in
question. However, it can be said that in some cases, medical discipline matters, while in
others, it does not.
A survey examining benzodiazepine prescribing decisions was conducted by
Brown and colleagues to assess the effect of clinical cues on decision making. Also
included in the analysis were physician variables such as year of medical school
graduation, specialty, clinical interest, and other demographic information. The sample
of 226 was drawn from the staff directory at a Midwestern U.S. medical school.
Recruitment into participation included two written invitations to schedule interviews,
and a written version of the questionnaire sent to non-responders. One hundred and three
physicians in various specialties completed the survey via interview, and 13 filled out the
written version. Those who answered the written version did not differ in responses from
those who completed interviews (Brown, et al, 1997). Medical disciplines represented in
this study included: allergy, cardiology, endocrinology, family practice, gastroenterology,
general internal medicine, hematology, infectious disease, nephrology, neurology,
oncology, psychiatry, pulmonology, rehabilitation, and rheumatology. The highest
number of respondents were in family practice (20 respondents), psychiatry (15
respondents), and general internal medicine (13 respondents) (Brown, et al, 1997).
Eleven oncologists participated, and the rest of the specialties had 9 or fewer respondents
each (Brown, et al, 1997).
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A series of 24 patient cases was used to measure physician prescribing of
benzodiazepines while varying four factors: health status, psychiatric diagnosis, stability
of job and marriage, and short-term ability to work. Additionally, cues such as elevated
liver function tests, unstable blood pressure, and esophageal reflux, which along with
complaints of nervousness and insomnia can be suggestive of alcohol abuse, were varied
in the scenarios. Physician prescribing decisions were measured as level of agreement
with continued prescribing of a patient’s current therapy, using a scale of –5 (strong
disagreement) to +5 (strong agreement), with 0 eliminated in order to force a choice.
The dependent variable was agreement with continued prescribing. Variables of
diagnosis and presence of alcohol-related medical problems were found to be significant
at the 0.05 level (Brown, et al, 1997). Long-term social stability, recent function, and
interaction terms for alcohol-related medical problems with diagnosis were not
significant (Brown, et al, 1997). Also in the initial regression model were physician
characteristics of year of graduation from medical school and specialty, among others.
This study did not find these to be significant with regard to physician prescribing
decisions (Brown et al, 1997).
Many medical disciplines were included in this study. However, the patient case
scenarios were all about patients presenting specifically with psychiatric complaints.
While it is logical to include general practitioners and psychiatrists in this sample, it is
unlikely that some of the other specialties, such as allergy/immunology, would be making
decisions about prescribing benzodiazepines for these patients. It is unknown whether a

34
larger sample size with a more focused choice of medical disciplines included might
yield different results.
A survey of emergency department physicians also used vignettes to identify
factors influencing physicians’ decisions to prescribe opioids (Tamayo-Sarver, Dawson,
Hines, Cydulka, Wigton, Albert, et al., 2003). The purpose of this study was to
determine the effect of patient characteristics and diagnosis on physicians’ decisions to
prescribe opioids for patients. This was a large survey of 5,750 emergency physicians
systematically (every second name) selected from the American College of Emergency
Physicians (ACEP) membership list. The survey packet in this study included a cover
letter, the questionnaire, and a $2 bill for incentive (Tamayo-Sarver, et al, 2003). Nonresponders were sent a reminder postcard, and then a second questionnaire. The
researchers achieved a response rate of 53% (Tamayo-Sarver, et al, 2003).
Questionnaires were considered complete enough for analysis if one of the three vignettes
was answered. Three models were constructed, one for each of three diagnoses: ankle
fracture, migraine, and back pain.
Results showed that the patient characteristic of race/ethnicity was not significant
for any of the models; p-values for migraine, back pain, and ankle fracture were 0.65,
0.79, and 0.25, respectively (Tamayo-Sarver, et al, 2003).
In summary, there have been several studies examining factors that affect
physicians’ prescribing decisions under various conditions. These studies have suggested
that level of control of the medication, patient’s diagnosis, and patient’s history of
substance abuse may play a role in physicians’ decisions to prescribe controlled
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substances. Physician specialty and length of practice may or may not be important, and
patient race/ethnicity may not be important. In this study, all of these variables will be
put into the initial model except for patient race/ethnicity, which will be held constant.

3

Preliminary Study

CHAPTER 3
Preliminary Study
Note: This article will be forthcoming in the Journal of Addictive Diseases.

Overview
This chapter explains a preliminary study of package insert information on drug
abuse and dependence. At the time this dissertation was being written, the study had
been accepted for publication in the Journal of Addictive Diseases.

Background and Significance
Among the responsibilities of the United States Food and Drug Administration
(FDA) is that of ensuring the safety and efficacy of drugs that have a legitimate medical
use. Prescriber education is an integral part of facilitating the safe and proper use of
medications. The mechanism by which the FDA initially communicates information to
health care providers is the FDA-approved product labeling, also called the package
insert. The package insert provides information on the risks and benefits of using a
particular substance, the approved indications, dosing, pharmacokinetics, side effects,
pharmacology, contraindications, warnings, and precautions. Abuse and dependence
potential of a drug is also included in this information. Prescription drug abuse is an ongoing problem in the United States (Jongston, O’Malley, Bachman, Shulenbert, 2004;
36
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Mohler-Kuo, Lee, Wechsler, 2001). Because the FDA’s initial communication of drug
information to prescribers is through the package insert, it is imperative that the drug
abuse and dependence information contained in these package inserts use clear and
consistent language in order to be clinically useful.
Scientists have long debated the definitions of addiction, abuse, and dependence.
Numerous review and opinion papers propose definitions and appropriate use of the
words, and committees have been formed in an effort to standardize terminology (Dodes,
1996; Maddux and Desmond, 2000; Peele, 1977; Goodman, 1990; Savage, Joranson,
Covington, Schnoll, Heit, Gilson, 2003; Trachtenberg). Use of these terms, however,
continues to be an issue. A qualitative assessment of information about opioid use and
addiction potential in fourteen textbooks was performed by Ferrell et al. They found that
information, based on the researchers’ definition of “addiction,” was more often
inaccurate than not, and highly varied in how “addiction” was defined and used (Ferrell,
McCaffery, Rhiner, 1992).
Considering the history of inconsistent use of terminology related to substance
abuse and dependence, variability could be carried over into physician opinions. In a
survey of 500 physicians, researchers gathered data about general knowledge of
practitioners in the area of pain management, including the definition of “addiction” and
legal issues associated with prescribing controlled substances. Survey respondents
defined addiction in a variety of ways even when it was presented as a multiple choice
question (Greenwald, Narcessian, Pomeranz, 1999).
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The Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text
revision (DSM-IV-TR) does not use the word “addiction,” but instead gives criteria for
“substance abuse” and “substance dependence,” respectively (American Psychiatric
Association, 2000). Both are described as maladaptive patterns of substance use, the
symptoms of which differ slightly in intensity and nature.
The discrepancies in definitions for addiction, dependence, and abuse and usage
among textbooks and the primary literature could potentially carry over into product
labeling (package inserts). This can lead to differences of opinion among prescribing
physicians about a drug’s potential for abuse or dependence and influence prescribing
decisions. Other health care professionals (e.g., pharmacists, nurse practitioners) also
interpret package insert information. Variability in definitions and usage can affect both
prescribing and patient counseling information.
No published systematic evaluations of abuse and dependence potential
information in package inserts were found in a Medline search. There have been studies
of other categories of information in product labeling (e.g., pregnancy, hepatotoxicity) all
of which revealed deficiencies in the information in question (Uhl, 2002; Spyker, Harvey,
Harvey, Abernathy, 2000; Hung, Ponto, Gadient, 2004; Willy, Li, 2004; Mullen,
Anderson, Kim, Blanc, Olson, 1997). One such study reported that only 11% of a sample
of over 100 pregnancy category X drugs contained, beyond a box warning or
contraindication for use in pregnancy, specific risk management strategies such as
obtaining negative pregnancy tests before initiation and during drug therapy (Uhl 2002).
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A study by Spyker et al. assessed clinical pharmacology information in 76
package inserts from the 1996 edition of the Physicians’ Desk Reference (PDR).
Researchers in this study created a scale for the evaluation of the information and
assigned each package insert a percentage score for containing predetermined
information, such as identification of the active agent, its mechanism of action, and
duration of effect. The authors reported a median percentage score of 31% and
concluded that package inserts are deficient in clinical pharmacology information
(Spyker et al., 2000).
Hung et al. identified five categories of problematic instructions in the package
insert information for the preparation of radiopharmaceuticals: absent or incomplete,
restrictive, inconsistent, impractical, and vague directions. These researchers concluded
that the information provided in FDA-approved product labeling should be considered
guidance and not a requirement, and that nuclear pharmacists and physicians should be
able to deviate from the methods provided in the package insert (Hung, et al, 2004).
Another study of FDA-approved product labeling examined the consistency and
quality of information about hepatotoxicity for 95 prescription drugs from the 2000 PDR
with a checklist used to create an informativeness score. The mean informativeness score
was 35% and the authors concluded that information provided in labeling is variable but
may be improved by increasing consistency of information on hepatotoxicity in the
product labels (Willy, Li, 2004).
A comparison of overdose management information found in the PDR to
toxicology references indicated that there are deficiencies in PDR overdose treatment
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strategies. The authors report that almost half of the evaluated PDR entries
recommended either ineffective or contraindicated therapies (Mullen et al., 1997). This
study draws attention to the possibility of clinically inaccurate information in package
inserts.

Objective and Hypotheses
Based on the historical lack of consensus on the use of drug abuse and
dependence-related terminology and the inadequacy of package insert content suggested
by prior reviews thereof, an evaluation of the drug abuse and dependence information in
package inserts was conducted. The purpose of this project was to describe and evaluate
package insert content with regard to abuse and dependence potential for drugs that are
dispensed in community pharmacies. Package inserts for products in higher controlled
substance schedules (those with lower schedule numbers which have higher abuse
potential) should have stronger warnings and more information about drug abuse and
dependence than those products with less abuse potential.

Methods
The American Hospital Formulary System (AHFS) 2003 was used to identify
drugs that act in the central nervous system (CNS). The following CNS-active drug
classes were selected:
•

Analgesics and anti-pyretics: opiate agonists and partial agonists
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•

Anticonvulsants: barbiturates and benzodiazepines

•

Anorexigenic agents, respiratory stimulants, and cerebral stimulants

•

Anxiolytics, sedatives, and hypnotics: barbiturates, benzodiazepines

•

Miscellaneous central nervous system agents

Drugs in these classes were then cross-referenced with the 2003 Electronic
Physicians’ Desk Reference (E-PDR) (AHFS, 2003, Medical Economics Company,
2003). Drugs with brand names and full package inserts were included in the study.
Generic products and injectable preparations were excluded. A full list of package inserts
included in the study is included as Appendix A of this document.
Microsoft AccessTM was used to create a database. The drug’s generic and brand
name, manufacturer, Federal Controlled Substance Act (CSA) schedule, and AHFS
therapeutic classification were recorded. Package inserts in the E-PDR were reviewed by
one researcher (LBP). Information pertaining to drug abuse and dependence was then
extracted into the database.
In the first part of the study, each package insert was evaluated for content. The
main parameter assessed was the presence or absence of primary terms: addiction,
dependence, physical dependence, and psychological or psychic dependence. Also noted
was the presence or absence of other terms: habituation or habit-forming, tolerance,
withdrawal, abstinence syndrome, drug-seeking behavior, misuse, abuse, diversion,
craving, and illegal or illicit use.
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A coding system was then created to further describe how the above terminology
was used in the package insert. For example, it was noted whether or not the term was
described or defined in the package insert. The strength of the warning about abuse
potential was subjectively assessed for each package insert. If the phrase “may cause
dependence” was used, the warning was considered mild. Statements that the drug “has
been abused” or “has caused dependence” indicated a moderate warning. Strong
warnings about abuse potential were marked by phrases such as “actively sought out by
drug abusers, diversion not limited to those with a history of substance abuse”, and the
words “severe” or “extensive” being used to describe dependence on the drug.

Other

codes included: the presence or absence of terminology indicating either evidence of no
abuse or dependence potential or lack of information about abuse or dependence
potential, the presence or absence of warnings regarding tapering of doses or
consequences of abruptly stopping medication, and the presence of an entire section
designated for abuse and dependence information. A complete list of codes and their
meanings is available as Appendix B of this document. The number of sentences
dedicated to information about abuse and dependence potential was recorded as a method
of quantifying the amount of information in the package insert related to drug abuse or
dependence.
Descriptive statistics were used to characterize the data. Frequencies were
reported for parameters recorded as present or absent. Central tendency and spread of the
amount of information relating to drug abuse and dependence was quantified by median
and range for number of sentences since the data were not normally distributed. Kruskall-
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Wallis was used to compare the amount of information across schedules for controlled
substances (CII-V) and across warning strength categories. Spearman’s Rho correlation
was used to determine strength and significance of time trends in the amount of
information using the original drug approval date and the date of the last label revision
because the data for these continuous variables were not normally distributed.

Results
Of the 77 entries in the package insert database, 40 were opiate agonists, 18 were
stimulants, and the remainder fell into one of the following categories: opiate partial
agonists, anticonvulsants, anxiolytic/sedative/hypnotics, or miscellaneous CNS agents.
Twenty-nine records were in schedule II, 24 in schedule III, 15 in schedule IV, 1 in
schedule V, and 8 were non-scheduled. Table 3.1 shows the number of package inserts in
each AHFS class and each Federal Controlled Substance Act schedule (CSA schedule).
Table 3.1 Frequency of package inserts included in study of drug abuse and dependence warnings as
a function of AHFS classes and CSA schedules

AHFS Class / Federal Controlled Substance Act
Schedule
Analgesics: Opiate Agonists
Analgesics: Opiate Partial Agonists
Anticonvulsants: Barbiturates
Anticonvulsants: Benzodiazepines
Anorexigenics, Respiratory & Cerebral Stimulants
Anxiolytics, Sedatives, Hypnotics: Barbiturates
Anxiolytics, Sedatives, Hypnotics: Benzodiazepines
Anxiolytics, Sedatives, Hypnotics: Miscellaneous
Miscellaneous CNS agents
Total

CII

CIII

CIV

CV

NS

Total

18
0
0
0
11
0
0
0
0
29

18
0
0
0
2
3
0
0
1
24

1
3
0
1
4
0
4
2
0
15

1
0
0
0
0
0
0
0
0
1

2
0
1
0
1
1
0
3
0
8

40
3
1
1
18
4
4
5
1
77
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Of the eight non-scheduled products, two were opiate agonists (tramadol), five
were anxiolytic/sedative/hypnotics (phenobarbital [2], hydroxyzine [2], promethazine
[1]), and one was a stimulant (caffeine).
Table 3.2 shows the frequencies of a section designated specifically for
information about drug abuse and dependence for each AHFS class and CSA schedule.

Table 3.2 Frequencies of sections specifically dedicated to information about drug abuse and
dependence for each AHFS class and CSA schedule

Class
Opiate Agonists
Opiate Partial Agonists
Anticovulsants: Barbiturates
Anticonvulsants: Benzodiazepines
Stimulants
Anxiolytic, Sedative, Hypnotics: Barbiturates
Anxiolytic, Sedative, Hypnotics: Benzodiazepines
Anxiolytic, Sedative, Hypnotics: Miscellaneous
Miscellaneous CNS agents
Total

# Inserts
37/40
3/3
0/1
1/1
14/18
¾
¾
2/5
1/1
64/77

Percentage
92.5
100
0
100
77.8
75
75
40
100
83.1

Schedule
CII
CIII
CIV
CV
Non-scheduled
Total

25/29
24/24
12/15
1/1
2/8
64/77

86.2
100
80
100
25
83.1

About 83% of the 77 package inserts had a section dedicated specifically to drug
abuse and dependence information. Most opiate agonists and stimulants had a dedicated
section for drug abuse and dependence information. There was a dedicated section for
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drug abuse and dependence information in 100% of the inserts in CSA schedules III and
V, although there was only one schedule V insert.
Table 3.3shows the frequencies of package inserts in each AHFS class and CSA
Schedule containing primary terminology.

Table 3.3 Appearance of primary abuse and dependence-related terminology in package inserts
from AHFS classes and CSA schedules

Class

Addiction

Dependence
25
2

Physical
Dependence
39
3

Psychological
Dependence
36
2

Opiate Agonists
Opiate Partial
Agonists
Anticovulsants:
Barbiturates
Anticonvulsants:
Benzodiazepines
Stimulants
Anxiolytic, Sedative,
Hypnotics:
Barbiturates
Anxiolytic, Sedative,
Hypnotics:
Benzodiazepines
Anxiolytic, Sedative,
Hypnotics:
Miscellaneous
Miscellaneous CNS
agents
Total:
Schedule
CII
CIII
CIV
CV
NS
Total

13
0

Abuse
29
3

0

0

0

0

0

1

1

0

0

0

1
2

14
1

2
3

16
3

17
3

1

4

4

4

1

2

2

1

0

2

0

1

0

0

1

20

50

52

61

56

11
4
5
0
0
20

24
13
11
1
1
50

18
21
10
1
2
52

26
22
10
1
2
61

27
15
11
1
2
56
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The word “addiction” appeared in 26% of the 77 records (13/20 were opiate
agonists). The word “dependence” without distinction for physical or psychological was
found in 65% of the 77 records (25/50 were opiate agonists, 14/50 were stimulants). Of
the primary terms, “psychological dependence” appeared most frequently (61/77 inserts).
However, terms frequently associated with the concept of psychological dependence,
such as craving and drug-seeking behavior, appeared only rarely (3 and 7 inserts,
respectively). The frequencies for presence of other terms are found in Table 3.4. The
two most commonly used of the other terminology were “tolerance” and “withdrawal.”

Table 3.4 Appearance of other abuse and dependence-related terminology in package inserts

Term
Tolerance
Craving
Withdrawal
Abstinence Syndrome
Misuse
Diversion
Habit-forming/Habituation
Illicit/Illegal Use
Drug-seeking Behavior

Number of Package
Inserts (n=77)
60
3
53
14
16
4
25
2
7

Percentage
(%)
77.9
3.9
68.8
18.2
20.8
5.2
32.5
2.6
9.1

Warning strengths are summarized for each AHFS class and CSA Schedule in
Table 3.5.
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Table 3.5 Strength of warnings about drug abuse and dependence appearing in each AHFS class and
CSA schedule

Class
Opiate Agonists
Opiate Partial Agonists
Anticovulsants: Barbiturates
Anticonvulsants: Benzodiazepines
Stimulants
Anxiolytic, Sedative, Hypnotics: Barbiturates
Anxiolytic, Sedative, Hypnotics: Benzodiazepines
Anxiolytic, Sedative, Hypnotics: Miscellaneous
Miscellaneous CNS agents
Total
Schedule
CII
CIII
CIV
CV
Non-scheduled
Total

Strong
3
1
0
0
7
0
0
0
1
12

Moderate
10
2
0
0
9
3
2
0
0
27

Mild
27
0
1
1
1
1
2
2
0
34

Total
40
3
1
1
17*
4
4
2*
1
73*

6
2
2
0
2
12

12
7
7
1
0
27

11
15
6
0
2
34

29
24
15
1
4*
73*

*The package inserts that had no warning about drug abuse were all non-scheduled; one for caffeine, 1 for
promethazine, and 2 for hydroxyzine.

Of those inserts with mild warnings, 88.2% were opiate agonists. Of those with
strong warnings, 58.3% were stimulants, 33.3% were opiate agonists (2/4 were nonscheduled), and 8.3% (1 insert) was an opiate partial agonist. The strongest warnings
appeared in cerebral stimulants and opiate agonists; however, the strength of warnings
within AHFS classes was variable, particularly for the opiate agonists. Many of the
schedule II opiate agonists had mild warnings while two of the four opiate agonist/partial
agonist products with strong warnings were non-scheduled (both contain tramadol).
Strength of warning was not significantly different across CSA schedules (p=0.069), nor
did it have any correlation with original approval date (p=0.610).
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Eighteen (23.4%) package inserts indicated that abuse, dependence, or addiction
was rare. All but one of these 18 were opiate agonists. Thirteen said that “dependence”
was rare, and 5 stated that “addiction” was rare. The two that asserted “abuse” was rare
also stated that “dependence” was rare.
A boxed warning about drug abuse and dependence appeared in 51.7% of the
schedule II drug records. The percentage of records with boxed warnings in the
remaining schedules was less than 15% each.
The overall median number of sentences on drug abuse and dependence was 17
with a range of 0-66. The greatest variability was found among the opiate agonists
(median 20, range 7-66 sentences). There was high variability in all schedules except
schedule V, in which there was only one entry (14 sentences). Table 3.6 shows the
median and range of sentences found in each CSA Schedule.

Table 3.6 Number of sentences about drug abuse and dependence in each CSA schedule

Schedule/Number of Sentences
CII
CIII
CIV
CV
Non-scheduled

Number of Sentences: Median (Range)
15 (5-66)
19 (9-48)
15 (7-62)
14 (only one package insert was a CV)
1 (0-28)

The amount of information in controlled substances (scheduled II-V) did not
significantly vary across CSA schedule (p=0.443), nor was it significantly different
across warning strength categories (p=0.821). There was a positive significant
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correlation between the number of sentences and the original drug approval date
(Spearman’s rho=0.429, p<0.001). On the other hand, the correlation between the
number of sentences and year of most recent label revision was not significant
(Spearman’s rho= -0.040, p=0.749).

Discussion
Variability in information about drug abuse and dependence potential is high and
can be confusing for health care professionals. Neither the strength of warning nor the
amount of information dedicated to drug abuse and dependence significantly differed
across CSA schedules, indicating that neither the amount of information on drug abuse
and dependence nor the strength of the warning accurately reflects the CSA schedule into
which a drug falls. For example, two inserts with strong warnings and a moderate amount
of information (21 and 28 sentences, respectively) were non-scheduled. The warnings
and amount of information in these cases seem to contradict the implication that the drug
has little to no abuse liability based on its non-scheduled status. An explanation for the
lack of relationship between warning strength and schedule control would be an overall
increase in warning strength over time; however, original approval date did not correlate
with warning strength.
The sample of inserts in this study is heavily weighted toward opiate agonists,
with stimulants being the second largest group. While most package inserts explain or
describe physical dependence, tolerance, and withdrawal, there is a lack of information
about psychological dependence, which was the most frequently appearing of the primary

50
terms. The word “addiction,” which is not universally defined and does not appear in the
DSM-IV-TR, is frequently used. Many words commonly associated with the idea of
psychological dependence and addiction, however, are rare.
The stimulants had stronger warnings and more boxed warnings about drug abuse
and dependence than did opiate agonists. Not surprisingly, however, the opiate agonists
had more information about physical dependence, tolerance, and withdrawal; however,
twelve opiate agonist package inserts indicated that “dependence” was rare.
The amount of information, quantified by the number of sentences, is also highly
varied, even within package inserts for the same drug. For example, there were six
entries for products containing oxycodone, and the number of sentences about drug abuse
and dependence ranged from 7-66. For morphine, six entries ranged from 9-46
sentences.
The amount of information on drug abuse and dependence increased over time
with respect to the original approval date of the drug, but not the date of the latest label
revision. It is possible that the overall length of package inserts has also increased over
time as approval requirements for detailed information also increase. Thus, it is possible
that the proportion of total package insert information related to drug abuse and
dependence information has not changed; however, this remains unknown as the overall
length of the package inserts was not collected in this study.
There are several limitations to this study. The E-PDR was the only source of
package inserts used and only brand named drugs were included. Because manufacturers
pay to have information published in the PDR, the content changes from year to year.
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Consequently, a sample using the same selection criteria with a PDR from another year
could yield a different number of package inserts and distribution of schedules and
classes. Likewise, the package inserts themselves may have been revised and differ from
those collected in this data set in 2003. As a result, the sample of package inserts included
in this study may not be representative of all of the drugs currently on the market.
Although objective criteria were applied in the determination of warning strength, it was
highly subjective, and only one person evaluated the package inserts. Finally, the sample
of package inserts used here was heavily weighted towards opiate agonists, with very few
drugs in some of the other AHFS classes. This makes it difficult to draw generalized
conclusions about those classes with very few package inserts. The same holds true for
CSA Schedules; well over half of the package inserts were in schedules II and III, making
it difficult to draw conclusions about variability within the other schedules.

Conclusion
Evaluation of 77 package inserts for CNS-active drugs demonstrated high
variability in terminology related to drug abuse and dependence. The confusion
generated by this inconsistency can affect prescribing decisions of currently practicing
physicians, patient counseling by pharmacists and other health care professionals, and the
education materials that students in the health care arena receive. Consequently, the
ambiguity and complexity of understanding drug abuse and dependence and its treatment
is perpetuated.
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The inconsistency found in this study indicates that package inserts are not a
clinically useful source of information about abuse and dependence liability of
prescription drugs in the U.S. It then becomes important to determine if this variability
also appears in health care provider’s opinions about the utility of information provided
in package inserts, and to discover what sources of information are used to gain
knowledge about abuse and dependence potential of prescription drugs. If, for example,
the CSA schedule itself is significantly important to health care providers, this places
great importance on the application of scientific information available when assigning
schedule control during the approval process (Balster and Bigelow, 2003). Until
standardized, common language is in place, this variability will continue and perpetuate
confusion about drug abuse and dependence. It is imperative to develop common
language for use in package inserts to improve communication about abuse and
dependence potential of prescription drugs and further attempt to prevent prescription
drug abuse.

4

Methods

CHAPTER 4
Methods

Overview
This chapter describes the methods used to meet the objectives stated in Chapter
1. After the objectives are restated and briefly addressed, details of the sampling frame
and scope of the project, the development and piloting of the questionnaire, the survey
process, and data analysis are presented.

Summary of Objectives
Objective 1:

Describe how physicians define the terms drug dependence and addiction.
Physicians were asked to choose factors they felt were necessary for the

clinical states of drug dependence and addiction to exist. Frequencies were
reported for descriptive purposes.
Objective 2:

Characterize sources used by physicians for drug abuse and dependence

and other drug information.
Physicians were asked to indicate how frequently they used various
sources for drug abuse and dependence information and other drug information.
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Mean values for these were calculated for the purpose of more accurately ranking
the sources physicians consult.
Objective 3:

Portray the scope of the problem of varied terminology in package inserts

by characterizing its effects on physician prescribing decisions when modeled
with covariates of physician and patient characteristics.
Physicians were presented with a series of four case scenarios with
package insert excerpts representing a medication given to the patient. Physician
prescribing decisions were measured as comfort level with a prior physician’s
choice, likelihood of refilling the prescription, and likelihood of choosing the drug
if the respondent was the first physician to see the patient. Additionally,
physicians rated how useful they find a particular package insert excerpt to be in
making a clinical decision.
For physician, patient, and package insert characteristics, regression
models tested whether coefficients were equal to zero. Interactions for the
variables history of substance abuse with type of pain and strength of warning
were tested for coefficients of zero as well.
Objective 4:

Provide groundwork for research designed to evaluate and develop more

useful package inserts.
Areas for future research are discussed in Chapter 6.
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Sampling Frame and Scope
The sampling frame consisted of physicians currently licensed and residing in the
Commonwealth of Virginia as of October 2005. At the time the study was started, there
were 34,694 physicians with M.D. or D.O. degrees in the Virginia Department of Health
Professions database, available online at http://www.vahealthprovider.com/search.asp. A
database containing each physician’s name, primary practice address, license number,
date of issue, expiration date, specialties, and degree (M.D., D.O., Intern/Resident) was
created in Microsoft Access. Of the 34,694 physicians, 21,835 had Virginia addresses,
and 797 had licenses that were expired. There were 4,635 intern/residents. Those with
generalized specialties numbered 14,411.

Inclusion/Exclusion Criteria
Doctors of Osteopathy were included in the sampling frame as they have full
prescribing power. Interns and residents were excluded since they do not yet have
complete autonomy in decision making. Because of the nature of the patient cases
depicted in the questionnaire, only generalized specialties most likely to see the patients
presented were included in the sampling frame. Those specialties included were: general
practice, family practice, internal medicine, emergency medicine, public health, and
preventative medicine.
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Sample Size
The required sample size for a margin of sampling error of (5% for the population
size of 14,411 was 375. Based on a predicted response rate of 25-30%, 1248-1500
physicians were needed in order to yield the sample size. Equation 1 was used for this
calculation.

Ns =

N p p(1 − p )
2

(N p − 1)⎛⎜ B ⎞⎟ + p(1 − p )
⎝C ⎠

(1)

In the above equation, Ns is the required sample size, Np is the population size, p is the
proportion of the population expected to choose one of a two-response item, B is the
acceptable amount of sampling error, and C is the z-statistic associated with the chosen
confidence interval (Dillman, 2000). For this project, p was assumed to be 0.5, the
lowest variability in responses, which would increase the needed sample size. An
accepted error rate of +/-5% was used, and 1.96 was used as the z-statistic corresponding
with a 95% confidence interval. Because of budget and labor constraints, however, a
random sample of 1008 physicians was used, so that equal numbers of each of the 24
versions of the questionnaire were sent out.
The random sample is expected to reflect the population of actively licensed
physicians in general practice areas in the Commonwealth of Virginia with respect to
demographics and generalizability of results.
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Development of Questionnaire
The questionnaire was designed to gather information on physicians’ prescribing
decisions, opinions about package insert excerpts, sources used for drug information,
ideas about addiction and drug dependence, and various demographics. The
questionnaire presented physicians with four patient cases, each associated with a
different package insert excerpt, and a series of five questions related to each case. The
final section was designed to ascertain information on sources used for drug information,
the importance of certain factors in making prescribing decisions, ideas about drug
dependence and addiction, and to obtain demographic information. A complete version
of the final questionnaire can be found in Appendix C.

Section 1: Patient Case Scenarios
The first section of the questionnaire presented physicians with four patient case
scenarios and a package insert excerpt. Patient case scenarios were used to indirectly
assess how various patient characteristics might also influence prescribing decisions.
Patient characteristics included the type of pain and history of substance abuse.
The first patient characteristic was the type of pain being treated. The four levels
for type of pain were:
1) Acute, represented by a recent broken ankle,
2) Chronic, malignant/cancer pain,
3) Chronic non-malignant pain of known origin (CNMK), represented by
osteoarthritis, and
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4) Chronic non-malignant pain of unknown origin (CNMU), represented by lower
back pain of unknown etiology.
Levels for pain type were initially acute and chronic. However, chronic pain cannot
easily be represented by one condition, so three levels for chronic pain were defined.
Common complaints were chosen to represent chronic, non-malignant pain conditions.
The second patient characteristic varied in the case scenarios was history of
substance abuse. There is a wide spectrum of substance abuse history possible. The
length of time since a person has used, whether or not they are in a controlled
environment, extent of use, type of substance/s used, and relapse can all affect a
physician’s view of the risk of abuse for a patient. However, this was not the focus of
this study, and in order to maintain a reasonable number of variables, the patient’s history
of substance abuse was represented by one of three levels:
1) Current, described as occasional use for recreational purposes
2) Past, indicated by a previous use but not within the last 5 years,
3) No history of substance abuse.
Because patient demographics were not variables of particular focus in this study, the
patient’s age, sex, and ethnicity were kept constant. This also kept the number of
variables at a more manageable level. Based on United States Census Bureau
information from 2000, the patient was a 38 year-old Caucasian male. The four levels of
pain type and three levels of substance abuse history required a total of twelve patient
case scenarios in order for all combinations to be used. The patient case scenarios used
in the final questionnaire versions are available as Appendix D. A package insert excerpt
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representing a medication previously prescribed to the patient followed each case
scenario. Package inserts contained three variables:
1) Warning strength, classified as either “strong” or “not strong,”
2) Advice, which was either present or not present,
3) Definitions of terminology used in the package insert, also considered either
present or not present.
Each package insert was classified on these variables a priori independently by three
researchers (LBP, PWS, SEH). Strength of warning was initially classified as “mild,
moderate, or strong” but later collapsed into two categories. Initially, definitions were
counted, but this was also collapsed into two categories of “present” and “not present.”
Criteria for classification were as follows:
1) Strength of the warning: Specifically, the statement regarding the dependence
potential of the drug.
Mild: Groups the drug in question with other drugs, taking focus off the drug
itself. Looked for phrases such as: "Drugs in this class have been associated with
dependence" "Like other drugs in this class, Drug X may cause dependence"
Moderate: Implicates the drug itself as the cause of dependence, but does not
indicate any severity. Phrases include "Drug X has been associated with
dependence" "Drug X can cause dependence"
Strong: Implicates the drug at hand with severe or debilitating dependence, or has
high dependence potential. Phrases include "Drug X has been associated with
severe dependence" "Drug X can cause dependence resulting in
severe/debilitating social/occupational dysfunction" and the like.

2) Direct advice given: Evaluates whether or not the information tells a physician
what to do in a specific situation.
Yes: The information uses the imperative/command form of a verb. For example
"Do this in this situation" or "Do not do thus and so"
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No: No direct advice given. This includes "suggestions" that do not directly tell a
physician what do to. For example, "Those with a history of substance abuse may
be at higher risk for psychic dependence", "Withdrawal symptoms may occur if
the drug is discontinued abruptly" or "Symptoms of withdrawal may be
relieved/caused by administration of..."

3) Definitions: Evaluation of definitions for terminology of interest. A "point" is
given for each term defined or described. Terms include: addiction, drug
dependence, physical dependence, psychic/psychological dependence, tolerance,
and withdrawal.

Based on three variables with two levels each, eight package insert excerpts were used to
include all possible combinations. The finalized versions of the package insert excerpts
are detailed in Appendix E of this document.
As described above, twelve patient case scenarios and eight package insert
excerpts were used. In order to ensure that all 96 combinations of patient case scenarios
and package inserts were used, 24 versions of the questionnaire, each with four different
combinations, were created. Each questionnaire version contained a patient case with
each type of pain, and at least one each of the three levels of substance abuse history.
Likewise, each version had at least one strong warning, at least one package insert
containing advice, and at least one package insert with definitions of terminology. A
4-point Likert scale was used with points labeled “not at all, not very, somewhat, and
definitely.” Survey respondents tend to gravitate toward middle responses (Dillman,
2000). Because the questions asked here were thought more likely to cause indecision,
which would render those responses useless for data analysis, a neutral response was not
provided as an option.

61
In addition to the three measures of prescribing decisions, physicians were asked
two additional questions at the end of each scenario about the package insert excerpts to
assess physician-rated usefulness and warning strength. The first was how useful the
package insert information was, and was measured with the same Likert scale described
above. The second question asked physicians to classify which Controlled Substance
schedule was most appropriate for the drug.

Section 2: Sources Consulted for Drug Information
Information on sources used for drug information was presented as a grid, where
physicians were to select how often they used various sources for drug abuse and
dependence information and for other information. Figure 4.1 shows the grid used.

Figure 4.1 Grid used for gathering information about sources consulted by physicians
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Section 3: Factors in Clinical Decision-Making
In this section, physicians were overtly asked to rate the importance of various
factors in their clinical decision-making. The factors represented the patient and package
insert characteristics presented in the patient case scenarios. They were:
1) Controlled Substance schedule,
2) Definitions of terminology provided in the package insert,
3) Patient’s history of substance abuse,
4) Presence of clinical advice in package insert information,
5) Type of pain being treated,
6) Warning strength in package insert information.

A 4-point Likert scale with points labeled “not at all important, somewhat unimportant,
somewhat important, and very important” was used. Again, no neutral response option
was provided.

Section 4: Definitions of Addiction and Drug Dependence
To characterize how physicians perceive the terms “addiction” and “drug
dependence,” a list of seven possible symptoms or conditions was presented. These
were:
1) Abuse,
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2) Craving,
3) Drug-seeking behavior,
4) Physical dependence,
5) Psychological dependence,
6) Tolerance,
7) Withdrawal.
Physicians were asked to choose which were necessary for drug dependence to exist, and
again for addiction. Respondents could choose all that apply.

Section 5: Demographic Information
Demographic information collected included physician gender, initial year of
licensure, medical specialty, estimated percentage of patients with a known history of
substance abuse, and region of practice. Initial year of licensure, medical specialty, and
estimated percentage of patients with a known history of substance abuse were openended to allow for more specific data collection. Region of practice was presented as a
list of eight areas corresponding with zones indicated on a map of Virginia. The regions
were labeled:
1) Northern,
2) Western,
3) Central,
4) Tidewater,
5) Southern,
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6) Southwestern,
7) Northern Neck,
8) Eastern Shore.

Pilot of Questionnaire
The development and pre-testing of the questionnaire occurred in the following
stages:
1) Review by committee: The review committee consisted of the five members of
the dissertation advisory committee plus one other survey researcher and a
practicing primary care physician. This committee, consisting of experts in the
areas of substance abuse research, survey methodology, clinical research, and
practice, allowed for feedback from a diverse background of expertise.
2) Survey feedback: A convenience sample of 5 physicians who agreed to the task
was asked to fill out the questionnaire and provide feedback upon completion.
This feedback was used to further polish the items and format of the
questionnaire. Responses on these questionnaires were not recorded for use in the
data analysis of the final survey, as the purpose of the procedure was to gain
insight into the strengths and weaknesses of the questionnaire itself. Comments
received by these physicians are provided in Appendix F of this document.
3) Final review by committee: A final review by the dissertation committee was used
to uncover typographical errors, incorrect numbering, and any other previously
overlooked mistakes before mailing occurred.
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4) Cover letter: A cover letter explaining the general purpose of the survey and
stressing the importance and appreciation of response and assuring anonymity
was written and approved by the committee. The finalized cover letter for the
first mailing is represented as Appendix G of this document.
5) In order to easily distinguish between versions of questionnaires upon return, four
different colors of paper were used for the covers, and six combinations of
location for the correspondence address and VCU Medical Center logo were used.

Survey Process
After approval was granted by the Institutional Review Board (IRB), the Tailored
Design Method suggested by Dillman (2000) was implemented. This method involves
multiple contacts to the selected sample of physicians and has been shown to increase
response rate (Dillman, 2000). Each of the randomly selected physicians was assigned a
number from 0001 to 1008. There were a total of four contacts. The first mailing packet
contained four items: a cover letter, a questionnaire, a stamped, addressed return
envelope, and a response postcard. The postcard, shown in Figure 4.2, included just the
physician’s code number and check boxes stating, “I have completed and returned the
questionnaire,” and “I do not wish to participate in this survey.” This postcard was also
stamped and addressed for ease of mailing. The cover letter and questionnaire
instructions indicated that the postcard was to be returned separately from the
questionnaire.
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Figure 4.2 Return postcard

The separate mailing of the questionnaire and the postcard both maintained total
anonymity and allowed for tracking of respondents. Physicians who mailed the return
postcard did not receive a replacement questionnaire in the third mailing, as described
below.
The second mailing occurred two weeks after the questionnaire packet was
mailed. A reminder/thank you postcard, shown in Figure 4.3, was sent to each physician
with the exception of refusals (i.e., those who had returned the postcard with the box
checked next to “I do not wish to participate in this survey”) and to whom the initial
mailing was returned as undeliverable.
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Figure 4.3 Thank you/reminder postcard

This postcard thanked those who completed the questionnaire and served as a reminder to
those who had not yet responded.
The third mailing was sent three weeks later to those who had not yet responded
and included a revised cover (Appendix H) letter and replacement questionnaire was sent
to those who had not yet responded. The fourth mailing was another reminder/thank you
postcard sent another three weeks later. This technique of multiple contacts was
employed to improve response rates as discussed by Dillman (2000).
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Data Entry and Analysis
Questionnaires were opened in batches of 10 or more at a time so that no postcard
returned could be matched with a questionnaire, further maintaining anonymity.
Questionnaires returned more than 4 weeks after the final mailing were not used in data
analysis. As postcards were returned, the matching entry in the database was coded with
a “Y” for those who responded, an “N” for those who indicated they did not wish to
participate in the survey, and an “R” for those returned as undeliverable.
SPSS for Windows 13.0 statistical software was used to analyze the data. A
questionnaire was considered complete if at least three of the patient cases were answered
and if responses were provided for sections 2, 3, 4, and at least 3 of the 5 questions in
section 5. Sections 2-5 consisted of the information about sources used for drug
information, importance of factors in making clinical decisions, definitions of addiction
and drug dependence, and demographics.
Categorical variables were coded as numbers, while numerical variables were
recorded directly. Indicator variables were created for categorical variables with more
than two categories. The codebook is available as Appendix I of this document.
Region of practice was collapsed into three categories: Southwestern, urban, and
other rural. Southwestern Virginia was used as the reference group because it was a
region of interest. Physician specialty or medical discipline was collapsed into four
categories: family practice, internal medicine, emergency medicine, and other.
Emergency medicine was used as the reference group for this set of indicator variables.
For type of pain, chronic, non-malignant pain of unknown etiology (CNMU) was the
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reference group because the other types of pain had a known cause. For substance abuse
history, “none” was the reference group as the other levels of the variable represented at
least some history of substance abuse.
Interaction terms were created for three sets of variables: history of substance
abuse with type of pain, history of substance abuse with warning strength, and type of
pain with warning strength. Because the indicator variables were used to create the
interaction products, there were a total of 11 interaction products entered into the model:
six representing history of substance abuse with type of pain, two representing history of
substance abuse with warning strength, and three representing type of pain with warning
strength. These were added into the model in three separate blocks.
Demographic information was characterized using descriptive statistics as
appropriate. Frequencies were reported for categorical variables of gender, specialty, and
region of practice. For the continuous variables of initial year of licensure and
percentage of patients with a known history of substance abuse, mean and standard
deviation or median and range were used as determined by normality.
Frequencies were reported for the terms physicians associated with drug
dependence and addiction, and for sources used for drug information.

Missing data:
Fortunately, the large majority of questionnaires returned were filled out
completely enough for analysis. Because of the small numbers of missing data on each
variable, the following techniques were used to deal with missing data:
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•

Initial year of licensure was replaced with the median

•

Sources grid: For the grid concerning sources used for drug information, it was
assumed that missing data were indicative of a “never” response, and was
therefore transformed in SPSS from “system missing” to “0.”

•

For case scenario questions: case scenarios left unanswered were dropped.

Regression Models
Linear regression models were used to describe the effect of the physician,
patient, and package insert characteristics on physician prescribing decisions. Four
models were evaluated, one for each of the prescribing decision measures, and one for a
sum scale measurement for willingness to prescribe. The last would be evaluated only if
the three individual measures were highly correlated with each other and had a reliability
of α ≥ 0.7.
The major dependent variable was a decision to prescribe medication. This was
measured in three ways:
1) Comfort level with a prior physician’s choice
2) Likelihood of refilling the prescription
3) Likelihood of choosing the drug if the respondent was the first physician to see
the patient.
Each model is represented by equation 2:

Ŷ = B1X1 + B2X2 + … + BkXk + B0

(2)
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In the above equation, Ŷ is the predicted y-value, B is an unstandardized regression
coefficient, k is the number of variables in the model, and B0 is the y-intercept (Cohen
and Cohen, 2003). Therefore, in the initial models, Ŷ represents the measure of
prescribing decisions (comfort level, refilling, and first-time prescribing), and in the
fourth model, it would represent the measure of willingness to prescribe. The B-values
are the unstandardized regression coefficients for each of the physician characteristics,
patient variables, and package insert variables.
Independent variables were blocked together into three categories: physician
characteristics, patient characteristics, and package insert excerpt characteristics, as
described above in the measures section. The first block of predictors entered into the
model was that of physician characteristics, which included year of initial licensure,
gender, region of state, medical discipline, and estimated percentage of patients with a
known history of substance abuse. The second block of independent variables for the
model included the patient characteristics, which were type of pain and history of
substance abuse. The third block of predictors was made up of the package insert
variables. This was the final block of main effects in the models because it was the focus
of the project and in hierarchical terms, its R2 value indicates the amount of variance the
package insert information provides over and above the other main effects. Strength of
warning was either “strong” or “not strong,” a presence or absence of advice, and
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presence or absence of definitions given in each excerpt. The interaction terms were
added as fourth, fifth, and sixth blocks.

5

Results

CHAPTER 5
Results

Response Rate
Of 1008 questionnaires mailed, 155 were returned undeliverable and 7 were
returned stating “retired” on the postcard, leaving an actual sample size of 846. A total of
273 questionnaires met the criteria for a complete questionnaire and were used for
analysis. Based on the sample size of deliverable questionnaires, the response rate was
32.3%. Eighty-three (9.8%) physicians returned the postcard with the box labeled “I do
not wish to participate in this survey” checked. Interestingly, more questionnaires were
returned than postcards. Although 277 questionnaires were returned before the cut-off
date of April 3rd, 2006, only 246 postcards indicating the questionnaire had been
completed were received. Figure 5.1 shows the numbers of questionnaires and postcards
returned. The postcards were the only means of tracking responders and non-responders.
Because more questionnaires than postcards were returned, some responders’
characteristics were accounted for as non-responders.
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Figure 5.1 Flowchart of questionnaire responses

1008 questionnaires
mailed

280 returned
questionnaires

83 postcards with
“do not wish to
participate”

162 physicians
not qualified
for study

155 returned
undeliverable

2 with <3
patient
scenarios
completed

2 with sections
2-5 not
completed

3 returned after
04/03/06

517 postcards not
returned
(non-responders)

7 postcards
indicating
“retired”

273 used for data
analysis
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Responders and Non-Responders
Although responders were tracked to prevent mailing second questionnaires to
responding physicians, postcards identifying the responders were separate from returned
questionnaires, maintaining anonymity of responders. Characteristics of responders and
non-responders were analyzed for significant differences on the variables of gender,
region of practice, and initial year of licensure. Table 5.1 displays these characteristics.
Chi-square analysis revealed no statistically significant differences between responders
and non-responders with respect to gender or region of practice. Although year of
licensure was a continuous variable, it was not normally distributed, dictating that a
nonparametric test was more appropriate. The Mann-Whitney U-test revealed that
responders had been practicing significantly longer than non-responders, with initial year
of licensure having median values of 1985 and 1992, respectively. Initial year of
licensure was also significant in the regression models, as discussed below. Although the
impact of the significant difference between non-responders and responders is unknown,
it would be expected that the data would shift toward increased prescribing, since this
was the case among responders.
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Table 5.1 Characteristics of responders and non-responders

Variable
Gender(%)
Male
Female
Unknown
Region of practice (%)
Urban
Southwestern
Other non-urban
Unknown
Year of licensure (median)

Responders

Non-responders

74.4
23.1
2.5

66.1
28.1
5.8

65.9
9.9
23.1
1.1
1985

67.2
7.0
20.7
5.1
1992

p-value
0.070

0.360

<0.001

Responding physicians reported a median estimate of 5% of patients they see
having a known history of substance abuse, ranging from 0%-100%. The interquartile
range was 2%-10%. The one physician that reported 100% was an addiction medicine
specialist. One physician reporting 75% of patients with a known history of substance
abuse participated in correctional facility work. This information was written in as a
comment by the respondents. Other respondent comments can be found in Appendix J of
this document.

Objective 1: Definitions of Addiction and Dependence
To gather information about physicians’ impressions of the terms “addiction” and
“drug dependence,” physicians were provided with a list of characteristics and asked to
check any features they felt were necessary for the condition in question to exist. These
characteristics included: abuse, craving, drug-seeking behavior, physical dependence,
psychological dependence, tolerance, and withdrawal. Table 5.2 shows the frequency
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with which each was chosen. More physicians associated abuse, craving, drug-seeking
behavior, psychological dependence, and withdrawal with addiction than with drug
dependence, while more physicians felt that physical dependence and tolerance were
necessary for drug dependence.

Table 5.2 Frequency of chosen factors necessary for addiction and drug dependence

Term
Abuse
Craving
Drug-seeking behavior
Physical dependence
Psychological dependence
Tolerance
Withdrawal

Drug dependence
Frequency (%)
89 (32.6)
121 (44.3)
116 (42.5)
207 (75.8)
198 (72.5)
175 (64.1)
175 (64.1)

Addiction
Frequency (%)
210 (76.9)
236 (86.4)
241 (88.3)
187 (68.5)
217 (79.5)
169 (61.9)
183 (67.0)

For the conditions of addiction and drug dependence, the terms physical
dependence, psychological dependence, tolerance, and withdrawal were chosen as
necessary by more than 50% of physicians. Abuse, craving, and drug-seeking behavior,
however, were chosen by more than 50% of physicians for addiction but not for drug
dependence.

Objective 2: Sources Used for Drug Information
Physicians were asked to rate the frequency with which they consult various
sources for drug abuse and dependence information, and other drug information.
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Frequency was defined as never (0), yearly (1), monthly (2), weekly (3), or daily (4).
shows the mean and median frequency for each source consulted for drug abuse and
dependence information and other drug information.

Table 5.3 Sources consulted by physicians

Source

Drug Abuse Info
Other Info
Mean (median) Mean (Median)
Manufacturer
0.15 (0)
0.39 (0)
Drug Information Center
0.21 (0)
0.33 (0)
Internet
1.03 (0)
1.55 (2)
Package Insert
1.32 (1)
1.95 (2)
Personal Digital Assistant
0.98 (0)
1.54 (0)
Pharmacist
1.27 (1)
1.96 (2)
Physicians’ Desk Reference
1.61 (1)
2.39 (3)
Other
0.40 (0)
0.49 (0)
As with the measure of factor importance, a mean was calculated for the
consulted source even though the frequency is on an ordinal scale. The mean was used
only for ranking purposes. For both drug abuse/dependence and other information, the
Physicians’ Desk Reference (PDR) was the most frequently used source. Pharmacists
and package inserts were the next highest ranking for both types of information.
Manufacturers and drug information centers ranked the least frequently used. For all
sources consulted, the frequency was lower for drug abuse/dependence information than
for other information, and the overall frequency of sources consulted was low. Most
physicians who marked a frequency other than “never” for the “Other” category did not
write in their other sources. Other sources reported by physicians listed in Table 5.4.
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Table 5.4 List of “Other” sources consulted by physicians for drug information

•
•
•
•
•
•
•

Poison Control Center
Pharmacology textbook
UpToDate online
Primary literature
“Drug reps”
“Medical students – PDA by proxy?”
“Unbiased sources”
Some of these sources could be classified in other categories: UpToDate could be

classified as an internet source, and drug sales representatives could be classified as
manufacturer contact.

Objective 3: Regression Models
Four regression models were evaluated. The dependent variables were all
measures of physician prescribing decisions: comfort with the prior physician’s choice,
likelihood of refilling the prescription, likelihood of prescribing if the respondent was the
first physician to see the patient, and willingness to prescribe. Answers to three questions
pertaining to prescribing decisions were on a 4-point Likert scale: not at all (0), not very
(1), somewhat (2), or definitely (3). The dependent variable in the fourth model,
“willingness to prescribe,” was created as a sum score from the first three variables,
which were highly correlated with each other. Reliability testing for the scale resulted in
a Crohbach’s alpha of 0.944. The correlation coefficients for comfort level with refill
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likelihood and first prescription likelihood were 0.844 and 0.862, respectively. The
correlation coefficient for refill likelihood and first prescription likelihood was 0.843.
For each model, the same six blocks of predictors were entered for hierarchical
regression analysis. Table 5.5 summarizes the variables in the blocks of predictors
entered into each model.

Table 5.5 Summary of variables entered into regression models

Block 1: Physician Characteristics
Gender
Initial year of licensure
Estimated percent of patients with a known history of substance abuse
Practice region (Southwestern, urban, other rural)
Medical discipline (emergency, family practice, internal medicine, other)
Block 2: Patient Characteristics
Type of pain being treated (acute, cancer, CNMK, CNMU)
History of substance abuse (none, past, current)
Block 3: Package Insert Characteristics
Strength of warning in package insert (strong, not strong)
Presence of direct advice in package insert (present, not present)
Presence of definitions in package insert (present, not present)
Block 4: Interaction terms for type of pain with history of substance abuse
Block 5: Interaction terms for type of pain with warning strength
Block 6: Interaction terms for history of substance abuse with warning strength
For nominal variables with more than 2 categories, indicator variables were
created. For a physician’s practice region, the reference group was Southwestern
Virginia, and indicator variables were designated for urban and other rural. For medical
discipline, emergency medicine (EM) was the reference group, with indicator variables
created for family practice (FP), internal medicine (IM), and other. Type of pain was in
reference to chronic, non-malignant pain of unknown etiology (CNMU) with indicator
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variables for acute, cancer, and chronic, non-malignant pain of known etiology (CNMK).
For the history of substance abuse, the reference group was “none,” and indicator
variables were created for past history and current use.

All four models displayed overall significance at p<0.001. For all four models,
the blocks for physician, patient, and package insert characteristics, and interactions
between pain and history of substance abuse were significant. The blocks for interactions
between warning strength with type of pain and with history of substance abuse were not
significant in any model. Table 5.6 shows the overall adjusted R2, R2 change, and pvalues representing the significance for each block of predictors for the four models.

Table 5.6 Statistics for predictor blocks for four initial regression models

Physician
characteristics
Patient
characteristics
Package insert
characteristics
Interactions:
type of pain with
history
Interactions:
type of pain with
warning strength
Interactions:
history with
warning strength
Adjusted R2

Comfort model
∆R2 (p-value)

Refill model
∆R2 (p-value)

1st doctor model
∆R2 (p-value)

Willingness
model
∆R2 (p-value)

0.036 (<0.001)

0.021 (0.006)

0.033 (<0.001)

0.032 (<0.001)

0.362 (<0.001)

0.377 (<0.001)

0.348 (<0.001)

0.339 (<0.001)

0.031 (<0.001)

0.023 (<0.001)

0.032 (<0.001)

0.031 (<0.001)

0.018 (<0.001)

0.010 (0.009)

0.018 (<0.001)

0.016 (<0.001)

0.002 (0.293)

0.002 (0.250)

0.001 (0.513)

0.002 (0.358)

0.001 (0.526)

0.003 (0.112)

0.000 (0.756)

0.001 (0.423)

0.435

0.420

0.417

0.466

82
Because the predictor blocks for interactions between warning strength with type
of pain and history of substance abuse were not significant, the individual regression
coefficients were not further examined. Appendix K contains unstandardized regression
coefficients, standard errors, and p-values for all of the predictors in significant blocks for
the four models.
Within the block of physician characteristics, neither gender nor estimated
percentage of patients with a history of substance abuse was significant in any model.
Initial year of licensure and medical discipline were significant for all four models.
History of substance abuse and type of pain being treated were significant in the patient
characteristics blocks for each model. Warning strength and the presence of definitions
were both significant in all four models. The presence of advice in the package insert
was significant for all but the refill model. Further exploration of the models follows.

Model 1: Comfort Level of Prior Prescription
For the first model, the dependent variable of physician prescribing decisions was
measured by the question “How comfortable are you with the prior physician’s choice of
medication for this patient?” The overall adjusted R2 indicates that 43.5% of the variance
in the level of comfort with a prior physician’s choice is explained by the physician,
patient, package insert, and interaction terms entered into the initial model. Because the
blocks for interaction terms for warning strength with type of pain and substance abuse
were not significant, they were not included in the final model. The final model, then,
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consisted of all predictors in the first four blocks described above. Based on the
unstandardized regression coefficients, the equation for the final model is:

Comfort level =
-0.093(gen) +0.11(yr) +0.091(urb) +0.166(rural) -0.335(FP) -0.342(IM) -0.306(other)
+1.125(acute) +1.437(cancer) +0.243(CNMK) -0.442(past) -0.500(curr) -0.270(str) 0.169(adv) -0.196(def) -0.355(ac*past) +0.198(ac*curr) +0.414(can*past)
+0.364(can*curr) +0.313(CNMK*past) +0.086(CNMK*curr) -21.069
(5.1)

Abbreviations used in the above equation are listed in Table 5.7 Estimated percent of
patients with a known history of substance abuse was not included in the equation
because the regression coefficient was 0.000.

Table 5.7 Abbreviations used in regression equation 5.1

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Gen = physician gender
§Yr = initial year of physician licensure
Urb = urban region of practice
Rural = other rural practice region
§
FP = family practice specialty
§
IM = internal medicine specialty
§
Other = other medical discipline
§
Acute = acute pain
§
Cancer = cancer pain
CNMK = chronic, non-malignant pain of known etiology
§
Past = past history of substance abuse
§
Curr = current history of substance abuse
§
Str = warning strength in package insert
§
Adv = advice in package insert
§
Def = definitions in package insert
Ac*past = acute pain with a past history of substance abuse
Ac*curr = acute pain with current recreational substance use
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Table 5.7 Abbreviations used in regression equation 5.1 (continued)

• §Can*past = cancer pain with a past history of substance abuse
• §Can*curr = cancer pain with current recreational substance use
• CNMK*past = CNMK with a past history of substance abuse
• CNMK*curr = CNMK with current recreational substance use
§
significant at p<0.05
The physician characteristics explain 3.6%, and patient characteristics explain
36.2% over and above the physician characteristics, based on the change in R2. The
package insert characteristics of warning strength, advice, and definitions, then, explain
an additional 3.1%, while the interactions between pain type and substance abuse history
add an additional 1.8% to the model. The p-values for the change in R2 were all <0.001.
Physicians who have been more recently licensed are more comfortable with a
prior physician’s choice. Acute and cancer pain significantly increased comfort level
when compared to chronic, non-malignant pain of unknown eitiology (CNMU). Chronic,
non-malignant pain of known etiology (CNMK) did not significantly affect comfort level
when compared to CNMU. Past or current history of substance abuse decreased comfort
level compared to patients having no history of substance abuse. Strong warnings, the
presence of advice, and the presence of definitions in the package insert excerpts
decreased physician comfort level with the prior physician’s choice of medication.
The reference groups for pain type and substance abuse history were CNMU and
no history of substance abuse. Two interaction terms were significant in the initial model
and were entered into the final model. The term for cancer pain and current history of
substance abuse became non-significant in the final model; however, the interaction
product for cancer pain and past history of substance abuse remained significant. This
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indicated that the importance of the patient’s history of substance abuse was dependent
on the type of pain being treated. In this model, cancer pain, regardless of history of
substance abuse, increases physicians’ comfort level when compared to a patient with
CNMU with no history of substance abuse. In other words, even though past and current
history of substance abuse decrease comfort level, this becomes less important if the
patient is experiencing cancer pain.

Model 2: Likelihood of Refilling
The second measure of physician prescribing decisions asked the question “How
likely are you to refill this prescription?” The initial model (i.e. with all six blocks of
predictors) for this question showed an overall adjusted R2 of 0.418, and the final model
had an adjusted R2 of 0.416. Physician characteristics explain just 2.1% in this model,
with patient characteristics adding 37.7%. Package insert characteristics contribute an
additional 2.3% over and above physician and patient characteristics. Interactions
between pain type and substance abuse history, while statistically significant, add another
1.0% of explanation of variance in frequency of refilling.
The resulting equation for the final model is depicted in equation 5.2.

Likelihood of refilling the prescription =
0.040(gen) +0.011(yr) -0.002(%) +0.104(urb) +0.147(rural) -0.177(FP) 0.161(IM) -0.193(other) +0.901(acute) +1.585(cancer) +0.290(CNMK) 0.281(past) -0.374(curr) -0.252(str) -0.103(adv) -0.153(def) 0.491(ac*past) -0.113(ac*curr) +0.244(can*past) +0.176(can*curr)
+0.113(CNMK*past) +0.001(CNMK*curr) -21.392

(5.2)
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Table 5.8 lists the abbreviations used in equation 5.2 and indicates which
regression coefficients were significant.

Table 5.8 Abbreviations used in regression equation 5.2

• Gen = physician gender
• §Yr = initial year of physician licensure
• % = estimated percent of patients with known substance abuse history
• Urb = urban region of practice
• Rural = other rural practice region
• §FP = family practice specialty
• §IM = internal medicine specialty
• Other = other medical discipline
• §Acute = acute pain
• §Cancer = cancer pain
• §CNMK = chronic, non-malignant pain of known etiology
• §Past = past history of substance abuse
• §Curr = current history of substance abuse
• §Str = warning strength in package insert
• Adv = advice in package insert
• §Def = definitions in package insert
• §Ac*past = acute pain with a past history of substance abuse
• Ac*curr = acute pain with current recreational substance use
• Can*past = cancer pain with a past history of substance abuse
• Can*curr = cancer pain with current recreational substance use
• CNMK*past = CNMK with a past history of substance abuse
• CNMK*curr = CNMK with current recreational substance use
§
significant at p<0.05
Reference groups for those predictors with indicator variables remained the same as in
the first model. For pain, CNMU was the reference group, for physician specialty,
emergency medicine, and for history of substance abuse history, “no history” was used.
As in the first model (comfort model), more recent licensure indicates that a
physician is more likely to refill the prescription presented in the case scenario. Family
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practitioners and internists are less likely to refill compared to emergency physicians.
Not surprisingly, both acute and cancer pain increase likelihood of the physician refilling
the prescription. CNMK was also significant in this model (p=0.029) but not for any
other model. Past and current substance abuse histories again prove to have a negative
effect on physician prescribing, as do strong package insert warnings and presence of
definitions. The interaction for acute pain with a past history of substance abuse in this
model was also significant, again suggesting that the importance of substance abuse
history depends on the type of pain being treated. In this model, the interaction suggests
that physicians are less likely to refill a prescription for acute pain if someone has a past
history of substance abuse than they are for a patient with CNMU and no history.

Model 3: Likelihood of First Time Prescribing
The third measure of physician prescribing decisions was based on the question
“how likely would you be to prescribe this medication if you were the first physician to
see this patient?” In this model, the adjusted R2 indictated that 41.8% of the variance in
first prescribing could be attributed to the variables in the final model. Again, various
aspects of physician, patient, and package insert characteristics proved to be important, as
did interaction terms for pain type and substance abuse history. The final model is
represented in equation 5.3. Table 5.9 defines abbreviations used and indicates
statistically significant variables.
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First prescribing likelihood =
-0.081(gen) +0.012(yr) +0.002(%) +0.132(urb) +0.231(rural) -0.181(FP) 0.239(IM) -0.205(other) +1.143(acute) +1.389(cancer) +0.181(CNMK) 0.370(past) -0.395(curr) -0.276(str) -0.175(adv) -0.175(def) -0.507(ac*past) 0.051(ac*curr) +0.376(can*past) +0.273(can*curr) +0.244(CNMK*past) 0.019(CNMK*curr) -21.623
(5.3)
Table 5.9 Abbreviations used in regression equation 5.3

• Gen = physician gender
• §Yr = initial year of physician licensure
• % = estimated percent of patients with known substance abuse history
• Urb = urban region of practice
• §Rural = other rural practice region
• §FP = family practice specialty
• §IM = internal medicine specialty
• Other = other medical discipline
• §Acute = acute pain
• §Cancer = cancer pain
• CNMK = chronic, non-malignant pain of known etiology
• §Past = past history of substance abuse
• §Curr = current history of substance abuse
• §Str = warning strength in package insert
• Adv = advice in package insert
• §Def = definitions in package insert
• §Ac*past = acute pain with a past history of substance abuse
• Ac*curr = acute pain with current recreational substance use
• §Can*past = cancer pain with a past history of substance abuse
• Can*curr = cancer pain with current recreational substance use
• CNMK*past = CNMK with a past history of substance abuse
• CNMK*curr = CNMK with current recreational substance use
§
significant at p<0.05
As in the first two models, more recent year of licensure is significant. The
interpretation for this model is that more recently licensed physicians would be more
likely to prescribe the drug if they were the first to see the patient presented in the case
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scenario than would physicians who have been practicing for a longer period of time. In
this model only, region had an impact. The reference group for region was Southwestern
Virginia. The interpretation of this regression coefficient would be that compared to
physicians in Southwestern Virginia, physicians in other rural areas are more likely to
prescribe the drug as the first physician seeing the patient. Family practice and internal
medicine specialties had a negative impact when compared with emergency physicians,
as did either current substance abuse or a past history of substance abuse. Again, the
presence of acute or cancer pain increased the likelihood of prescribing, and strong
warnings, presence of advice, and definitions in package insert information decreased
potential prescribing. As in the first two models, likelihood of prescribing is also
dependent on the interaction between type of pain and substance abuse history, and the
impact of substance abuse history on prescribing is dependent on the type of pain being
treated. Here, a past history of substance abuse has a negative impact if the pain type is
acute, but a positive impact if the patient is experiencing cancer pain as compared to a
patient with no substance abuse history and CNMU.

Model 4: Willingness to Prescribe
All three previous dependent variables gauge a physician’s willingness to
prescribe a drug for the case scenario presented. In this final model, physician
prescribing decisions were measured as a sum scale of the dependent variables in the first
three models. That is, a physician’s answers to the first three questions were added
together to create a “willingness score.” This was done after correlation and reliability
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testing indicated that the three prior measures were highly correlated with one another.
Correlation coefficients were all >0.80, and Cronbach’s alpha, a measure of reliability,
was 0.944. A higher score on the scale translated to being more willing to prescribe the
drug. The adjusted R2 for the final model indicated that 46.6% of the variance in
willingness to prescribe could be explained by the variables in the model. This
composite dependent variable model explained between 3.1% and 4.9% more variance in
physician prescribing than any of the individual dependent variables alone.
Equation 5.4 represents the regression model for willingness to prescribe, and
Table 5.10 shows abbreviations used in the equation and indicates significant variables.

Willingness to prescribe=
-0.134(gen) +0.034(yr) +0.327(urb) +0.546(rural) -0.693(FP) -0.742(IM) 0.710(other) +3.170(acute) +4.411(cancer) +0.713(CNMK) -1.075(past) 1.269(curr) -0.797(str) -0.448(adv) -0.524(def) -1.298(ac*past) +0.025(ac*curr)
+1.034(can*past) +0.816(can*curr) +0.670(CNMK*past)
+0.067(CNMK*curr)-64.092
(5.4)
Table 5.10 Abbreviations used in equation 5.4

•
•
•
•
•
•
•
•
•
•
•
•
•
•

Gen = physician gender
Yr = initial year of physician licensure
% = estimated percent of patients with known substance abuse history
Urb = urban region of practice
Rural = other rural practice region
§
FP = family practice specialty
§
IM = internal medicine specialty
§
Other = other medical discipline
§
Acute = acute pain
§
Cancer = cancer pain
CNMK = chronic, non-malignant pain of known etiology
§
Past = past history of substance abuse
§
Curr = current history of substance abuse
§
Str = warning strength in package insert
§
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Table 5.10 Abbreviations used in equation 5.4 (continued)

• §Adv = advice in package insert
• §Def = definitions in package insert
• §Ac*past = acute pain with a past history of substance abuse
• Ac*curr = acute pain with current recreational substance use
• §Can*past = cancer pain with a past history of substance abuse
• Can*curr = cancer pain with current recreational substance use
• CNMK*past = CNMK with a past history of substance abuse
• CNMK*curr = CNMK with current recreational substance use
§
significant at p<0.05

Results were similar to those of the other models. Significant positive predictors
of willingness to prescribe were initial licensure year and acute or cancer pain.
Significant negative predictors were medical discipline other than emergency medicine,
past substance abuse history or current substance abuse, strong package insert warnings,
and advice or definitions in package inserts. The interaction terms again indicated that
willingness to prescribe for someone with a history of substance abuse depended on the
type of pain being treated.

Usefulness of Package Insert Information
Physicians were asked to rate how useful they found the package insert
information provided in making a clinical decision for the patient. The same previously
described 4-point Likert scale ranging from “not at all” to “definitely” was used.
Physician ratings were collapsed into two categories as follows: not at all and not very
were collapsed into a category called “not useful,” while somewhat and definitely were
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collapsed into a “useful” category. Chi-square for physician-rated usefulness and the
presence of advice was performed and revealed a significant difference (Х2=11.43,
p<0.001).
Table 5.11 shows the frequencies of physician-rated usefulness for the presence or
absence of advice provided in the package insert.

Table 5.11 Contingency table for physician-rated usefulness and advice

No advice
Advice present

Not useful
173
136

Useful
344
427

Overall, more physicians rated package inserts as useful; however, the largest
number of package inserts rated as useful were those with advice present. The lowest
number in the contingency table is the frequency of physicians rating a package insert
with advice as not useful. More physicians rated package inserts as not useful when there
was no advice given than when advice was given; however, even when no advice was
present in the package insert, more physicians rated it useful than not useful.

Assessment of Instrument
Although warning strength for each package insert excerpt was determined a
priori, physicians were also asked to rate the warning strength by choosing the Controlled
Substance Act (CSA) schedule that they felt was most appropriate for the medication
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associated with the package insert excerpt provided. Responses were collapsed into two
schedule categories: schedule II and other. Warnings determined as “strong” by the
researchers should correspond with physicians choosing the highest control level, or CII.
Table 5.12 shows the frequencies of schedule choice and pre-assigned warning strength.

Table 5.12 Contingency table for researcher and physician-rated warning strength

Schedule II
364
Strong
147
Not strong

Other
177
389

Chi-square analysis revealed that the frequencies in each cell of the contingency table
were not the same (Х2=171.54, p<0.001). Examination of the contingency table
frequencies suggests that researchers’ and physicians’ ratings agreed.
A second assessment of the instrument examined regression coefficients with
ranking of factor importance. Physicians were overtly asked to rate the importance of
factors in their clinical decision making. If factors were rated as important by physicians,
then the rankings of the importance of the factors should correspond with the rankings of
the regression coefficients for the variables.

Table 5.13 shows the mean response for the six factors and the regression
coefficients for the corresponding variables in the final regression models. It is important
to note that while the scale on which the physicians rated the factors was ordinal, a mean

94
was calculated because it was being used only for the purpose of ranking the order of
physician-rated importance of these variables.

Table 5.13 Physician-rated importance of factors in clinical decision making and corresponding
regression coefficients

Factor in package insert
Type of pain being treated
(cancer, acute)
Patient’s history of substance
abuse (current and past)
Warning strength
Advice present
Definitions present

Mean
Physician
Rating
2.85
2.79
1.93
1.86
1.28

Regression Coefficients
Comfort
Refill 1st Doctor
1.279
0.891
-0.442
-0.426
-0.296
-0.173
-0.181

1.727
0.882
-0.390
-0.201
-0.274
-0.103
-0.145

1.445
1.018
-0.376
-0.251
-0.299
-0.169
-0.166

Scale
4.433
2.779
-1.124
-0.717
-0.850
-0.446
-0.487

Generally, the physician ranking of factor importance corresponded with the ranking of
the corresponding regression coefficient, with the exception of advice and definitions
present. Note that it is the magnitude of the regression coefficient that was taken into
account because the sign indicated only the direction of the relationship to the dependent
variable. Based on both physician rating and regression coefficients, the type of pain
being treated was clearly the most important factor, and warning strength was always
higher than either advice or definitions present. With respect to history of substance
abuse, at least one regression coefficient ranked higher than warning strength in all cases.
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Study Summary
This survey study was designed to elucidate several issues surrounding drug
abuse and dependence and physician prescribing behaviors, particularly as they relate to
information provided in package inserts. A total of 1,008 physicians practicing in the
Commonwealth of Virginia in general medical disciplines were mailed a questionnaire
packet. Several contacts were employed to increase responses, resulting in an achieved
response rate of 33.1%. Items on the questionnaire addressed physician prescribing
decisions, impressions of package insert information, ideas about addiction and drug
dependence, sources consulted for drug information, and demographics.

Research Objectives and Results
Objective 1: Definitions of Addiction and Drug Dependence
One of the objectives of this study was to describe how currently practicing
physicians view the terms “addiction” and “drug dependence.” Physicians more
frequently associated physical dependence and tolerance with “drug dependence” than
with “addiction,” suggesting that physicians tend to view drug dependence as a
physiological state rather than the substance use disorder described in the Diagnostic and
Statistical Manual of Mental Disorders (DSM). Abuse, craving, drug-seeking behavior,
95
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psychological dependence, and withdrawal were more frequently associated with
addiction than with drug dependence. This points to physicians viewing addiction as the
disease state of Drug Abuse or Drug Dependence as described in the DSM. This
disparity surrounding these terms can be confusing when reading package inserts that do
not further explain what is intended by “drug dependence” or simply “dependence.”
Because no specific statistical tests have been used to explore these data, the significance
of these apparent differences in physicians’ ideas about these terms remains unknown.
However, it is evident that many physicians do not appear to view the terms addiction
and drug dependence equally.

Objective 2: Sources of Drug Information
A second objective of this study was to describe sources that physicians refer to
for drug information. Results showed that the three most consulted sources were the
Physicians’ Desk Reference (PDR), package inserts, and pharmacists. It is important to
note that the PDR is in fact a collection of package inserts. This being said, it appears
that package inserts are an essential source of information for physicians, making
standardized terminology imperative for providing information to prescribers.
Pharmacists, another source of information for physicians, may also turn to the package
insert for drug information, although this has not been explored in the current study.
Overall, the frequencies with which physicians report consulting sources is low,
with median values for most sources translating to “never” or “yearly.” This begs the
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question as to why physicians are not consulting drug information sources, particularly at
a time when there are so many medications from which to choose?

Objective 3: Regression Models
Four regression models were used to examine physician prescribing decisions.
These models were: comfort with a prior physician’s choice, willingness to refill the
prescription, likelihood of prescribing as the first physician seeing the patient, and a sum
score of the first three measures. In all four regression models, the three blocks of main
effects predictors were significant, as was the added predictor block of an interaction
between type of pain and substance abuse history. Two other blocks of interaction terms,
one for warning strength with pain type and one for warning strength with substance
abuse history, were not statistically significant.
Initial year of licensure for physicians was consistently significant in all four
models and indicated that more recent year of licensure had a positive impact on
prescribing. That is, physicians who were more recently licensed tended to be more
comfortable with a prior physician’s choice, more likely to refill the prescription, and
more likely to prescribe the drug if initially seeing the patient. This was also reflected in
the fourth model which showed that physicians who have been more recently licensed
were more willing to prescribe the drug overall. This could be attributed to their more
recent education on pain management issues, or could be a reflection of deeper suspicion
or concern about substance abuse and dependence by physicians who have had more
years of experience.
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Physician specialty was also found to be significant in all four models. With
respect to emergency physicians, family practice and internists were less likely to be
comfortable with a prior physician’s choice, refill the medication, or to prescribe the
medication as the first physician. This was also demonstrated in the overall willingness
model. Emergency physicians may make decisions differently for several reasons. First,
they do not see the same patients on a regular basis. While there are those who tend to
use emergency rooms as primary care because of insurance issues, this is the exception
and not the rule for most individuals. Emergency physicians, then, do not tend to have an
ongoing relationship with their patients. The effect of this on prescribing decisions is
unknown and was not explored in this study. Additionally, emergency patients are
frequently discharged with instructions to follow-up with their regular physicians. In
other words, the emergency physician takes care of the immediate issue, but it is the
patient’s regular physician who continues to monitor the patient and maintain or change
drug therapy. The long-term monitoring that a primary care physician performs could
also explain differences in prescribing decisions between emergency physicians and other
general practitioners. The designation of “other” did not have significant impact in either
the refill or first physician models.
Region of practice was significant in only one initial model, and became
insignificant once entered in to the final model. It was thought that the problems with
Oxycontin® in Southwestern Virginia in recent years may cause physicians in that region
to make different decisions than those in urban areas or other rural areas of the
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Commonwealth. However, this proved to have almost no impact for the purposes of this
project.
Patient characteristics were clearly the most important block of predictors in these
models. For all four models, this block of predictors contributed the most to explaining
the variance. Physicians were more likely to prescribe for acute and cancer pain when
compared to CNMU in all four models; however, CNMK was not significantly different
from CNMU. In this survey, CNMK was presented as severe osteoarthritis unresponsive
to acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs). It is possible that
if a different diagnosis had been used, that CNMK may have played a larger role.
Different diagnoses of CNMK were not addressed in this study but could be important.
A patient’s history of substance abuse was also clearly important to physicians
when making clinical decisions about prescribing analgesics. Patients with a history of
substance abuse and those who currently use drugs recreationally might raise caution and
decrease a physician’s willingness to prescribe or refill a prescription for a controlled
substance, with respect to patients with no history of substance abuse. However, this
became less important when treating acute or cancer pain as opposed to CNMU, as
demonstrated by the significant interactions found in the models.
The variability in package insert information about drug abuse and dependence
was a main focus of this study. Variability was measured with three variables: strength
of the warning about drug abuse and dependence, the presence of advice in the package
insert, and definitions of terms used in the insert. This block of predictors was significant
in all four models. Table 6.1 Physician-rated importance of factors in clinical decision
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making and corresponding regression coefficients illustrates the amount of variance in
each model explained by package insert variability over and above physician and patient
characteristics.

Table 6.1 Physician-rated importance of factors in clinical decision making and corresponding
regression coefficients

Comfort
Refill
First physician
Willingness scale

R2 change
0.031
0.023
0.032
0.031

Significance
<0.001
<0.001
<0.001
<0.001

Between 2.3% and 3.1% of the variance in physician prescribing decisions could
be explained by the variability in the package insert. All three predictors were significant
in all models, except that the presence of advice did not have a significant effect on
physicians’ decisions to refill a prescription. The finding that the PDR and package
insert were ranked among the top three sources consulted for drug abuse and dependence
information suggests that package insert information on drug abuse and dependence was
important to physicians. This further underscores the need for standardization of
definitions of terms surrounding the issue of drug abuse and dependence and the need for
more useful information such as clinical advice to be included in package inserts.

Limitations of Study
Because the sampling frame for this study was limited to the Commonwealth of
Virginia, the results may not be generalizeable to a population of United States
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physicians. While the Commonwealth of Virginia does have urban, suburban, and rural
regions, and has areas that have had drug abuse issues, it is difficult to say how closely
Virginia physicians’ responses would represent those from other states without including
physicians from other areas.
It is unknown whether or not physicians’ responses to questionnaire items
about prescribing decisions reflect what they would actually do in clinical practice.
Many variables that may affect physicians’ prescribing decisions, such as the patient’s
gender, age, ethnicity, and socioeconomic status, were held constant in this survey
because they were not the focus of this study. Additionally, many other details present in
a clinical setting were left out in the interest of creating more concise scenarios. These
include lab results and further details about prior treatment received. Furthermore, a
physician cannot interact with nor observe behaviors of patients presented on a paper
questionnaire. All of these variables may affect decisions that physicians make about
prescribing.
The patients in the case scenarios in this study were all 38 year old
Caucasian males. Variables of patient age, race/ethnicity, and gender were kept constant
because they were not the focus of this study and to maintain a reasonable number of
variables examined. It is possible that these variables contribute to a physician’s decision
to prescribe opioids for pain, and keeping them constant could have decreased the
variance explained by the models presented here. However, it was felt defining the
patient variables was a better option than leaving them unknown and allowing each
physician to make different assumptions about patient characteristics.
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Physicians are often considered to be low responders in survey research. In this
survey, a response rate of 32.3% was achieved. While this seems to be low, several of
the articles reviewed surveyed physicians in a narrower sampling frame. These included
a single medical school (Brown et al., 1997), members of a professional organization
representing only one medical discipline (Greenwald et al., 1999), a small collaborative
research network (Potter et al., 2001), and a single metropolitan area (Davies et al.,
1997). People are more likely to respond to a survey that is of interest to them and is
being conducted by a group to which they feel some sense of loyalty. Therefore,
narrowing a sampling frame may increase response rate; however, generalizability of
results is sacrificed. With regard to sample size, the database from which the information
was drawn was not as up to date or accurate as believed, and decreased the reachable
sample size from 1008 to 846.
A large national study of physicians from various medical specialties obtained a
response rate of 27.46% (Turk et al., 1994). While this study had a lower response rate,
the sample size and sampling frame allowed the results to be generalized to a larger
population, assuming that non-response error was not higher than in the other studies.
Regarding this study, those holding MD and DO degrees are certainly not the only
professionals with prescribing power. This sampling frame excludes residents and interns
and those with limited prescribing power such as dentists, nurse practitioners, and
physicians’ assistants. These professions were excluded as they do not have full
autonomy in decision-making and therefore may not be able to answer some of the items
on the questionnaire. As previously mentioned, this survey sampled physicians in the
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Commonwealth of Virginia only, so those practitioners who are licensed or residing
outside of Virginia are not included in the sample. Thus, the results of this study could
not be easily generalized to all physicians in the United States. This project would,
however, serve as a springboard for a larger, national sample in the future.
There may be some non-response error in that physicians who responded had an
earlier year of licensure than did non-responders. The impact of this on the results is
unknown, but year of licensure was a significant predictor in all four models. Based on
the results of the responders and the difference in licensure year between responders and
non-responders, the models would err on the side of less prescribing.
With respect to other physician characteristics, there was no difference between
responders for region or gender. Region for non-responders was determined by the
researcher based on the ZIP code, but was subjectively reported by responders. It is
possible that the responding physicians view themselves as being in a different region
than the researcher would assign based on ZIP code. Names of non-responding
physicians were evaluated for likely gender by the researcher. Any names that were
gender neutral or foreign names that could not be assigned a gender were considered
unknown. It is possible that some non-responders were assigned to the incorrect gender
category. Based on the responses for medical discipline, it is apparent that board
certification does not always reflect a physician’s self-reported specialty. Medical
discipline for responders and non-responders was not evaluated.
Finally, it is possible that some items on the questionnaire were not measuring
what the researchers intended, or were interpreted differently by respondents.
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Specifically, three physicians made comments that indicate the item about classifying the
medication into a CSA schedule was misread as classifying which level of drug control
should be prescribed for the patient. It is possible that other physicians also misread this
item; however, the chi-square analysis performed relating warning strength to physicianrated schedule indicates that this was not the case.
The limitations of this study are only minor weaknesses. Sufficient power was
achieved in the study as evidenced by the significant findings in the regression models
and other statistical analyses performed.

Areas for Future Research
The final objective of this dissertation was to provide groundwork for
future research. This project contributes to the literature about factors affecting
physicians’ prescribing decisions by demonstrating that information presented about
medications can affect their decision-making process. Surveys of larger size and broader
sampling frame could support or refute the results found in this study.
Three areas of variability in package insert information concerning drug
abuse and dependence have been identified as significantly affecting the physician’s
perceptions of the medication. All three were measured only as nominal variables,
however, and further research into more specific aspects of warning strength, advice
given, and definitions relating to terms used in package inserts is warranted. Physicians
are not the only health care providers who consult package inserts for drug information.
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Research about how information is communicated to other health care professionals such
as nurses and pharmacists would also prove interesting.
During the course of the completion of this project, the Food and Drug
Administration (FDA) released statements on changes to the format of package inserts for
medications. Research on current package inserts can help to guide regulators in forming
new guidelines for updated package insert content. These new package inserts will then
need to be evaluated.

Conclusions
Many factors were identified as having an affect on physicians’
prescribing decisions. These include physician characteristics such as year of licensure
and medical discipline, patient characteristics relating to type of pain and substance abuse
history, and package insert information provided to physicians. The three areas of
package insert variability identified in this study were the strength of the warning about
substance abuse and dependence, the presence of clinical advice given, and the presence
of definitions of terms used in the package insert.
The terms “addiction” and “drug dependence” were generally not viewed
as interchangeable by physicians. Drug dependence was more associated with a
physiological state and addiction with a psychological state. Sources consulted by
physicians were varied, with the top three reported as the PDR, package inserts, and
pharmacists. This was true for both drug abuse/dependence information and for other
drug information. Physicians rated package inserts offering direct advice as more useful
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than those without any advice. Advice presented in package inserts was related to patient
counseling, prescribing to substance abusers, and how to treat withdrawal.
Overall, the two studies performed show that: 1) there is high variability in
drug abuse and dependence information in package inserts, 2) the package insert
continues to be an important source of drug information for physicians, and 3) package
insert information can affect a physician’s prescribing decisions. This could affect the
quality and safety of patient care. As the FDA revises the requirements for product
labeling for new medications, continued evaluation of the package inserts for clarity and
consistency is imperative.
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Generic Name

# Entries in database

Alprazolam

1

Amphetamine

1

Buprenorphine

1

Butalbital

2

Butorphanol

1

Caffeine

3

Chlorazepate

1

Clonazepam

1

Codeine

3

Dexmethylphenidate

1

Dextroamphetamine

3

Diazepam

1

Estazolam

1

Fentanyl

2

Hydrocodone

10

Hydromorphone

1

Hydroxyzine

2

Mepiridine

1

Methamphetamine

1

Methylphenidate

3

Modafinil

1

Morphine

6

Nalbuphine

1

Oxycodone

7

Oxymorphone

1

Pemoline

1
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Pentazocine

2

Pentobarbital

1

Phendimetrazine

1

Phenobarbital

2

Phentermine

2

Promethazine

1

Propoxyphene

2

Sodium Oxybate (GHB)

1

Tramadol

2

Zaleplon

1

Zolpidem

1
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Qualitative codes and meanings for Preliminary Study

Code

Meaning

AEAb

Abuse is listed in the adverse effects section of the package insert

AEAd

Addiction is listed in the adverse effects section of the package insert

AEPsD

Psychological dependence is listed in the adverse effects section of the
package insert

AEWD

Withdrawal is listed in the adverse effects section of the package insert

AntW

The package insert contains a warning about administering an antagonist

CompAbP

The abuse potential of the drug is compared to that of a known drug of
abuse

CompDep

The dependence potential of the drug is compared to that of a known
drug of abuse

CompNot

The package insert states that the drug is NOT like a particular drug of
abuse

CompPhD

The physical dependence of the drug is compared to that of a known
drug of abuse

CompPsD

The psychological dependence of the drug is compared to that of a
known drug of abuse

CompSP

The chemical structure and pharmacology of the drug are compared with
a known drug of abuse or a class of drugs with abuse potential

DTol

The word “tolerance” is discussed, described, or defined

D/C

The package insert contains a warning against abrupt discontinuation of
the drug

DChrInt

The package insert discusses, describes, or defines chronic intoxication

DIDOA

The package insert discusses drug interactions of the drug with other
drugs of abuse

DIDOAN

There is no discussion of interactions between the drug and other drugs
of abuse

DifAbAd/PhDT

There is a statement that abuse zdbgbbg

DifTolPhD/PsD

There is a statement that tolerance and physical dependence are different
from psychological dependence

DInWD

Withdrawal symptoms in infants are described

Disc +

The drug was discriminated as being similar to another drug of abuse

DiscHu –

The drug was not discriminated by humans as being similar to a known
drug of abuse
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DiscHu +

The drug was discriminated by humans as being similar to a known drug
of abuse

DphD

Physical dependence is discussed, described, or defined

DPsD

Psychological dependence is discussed, described, or defined

DWD

Withdrawal is discussed, described, or defined

DWDdog

The package insert indicated that a withdrawal syndrome was found in
dogs upon discontinuation of the drug

EqAddDDPsD

Addiction, drug dependence, and psychological dependence were
equated with each other

EqPsyDAd

Psychological dependence was equated with addiction

ExtUseW

There is a warning against extended use of the product

HospEDrpt

The package insert discussed Emergency room hospital visits associated
with the use of the drug

HowAb+W

The package insert describes or discusses how the drug is abused

HxDACa

The package insert indicates that the drug should be used with caution in
patients with a history of drug abuse

HxDACI

The package insert states that the use of the drug is contraindicated in
patients with a history of drug abuse

HxDAW

The package insert indicates that the drug should not be used in patients
with a history of drug abuse

Limit

The package insert gives a dose limit or time limit for the use of the drug

MBHF

The package insert contains the phrase “May be habit forming”

NDInWD

The package insert states that infants born from mothers using the drug
experience withdrawal, but symptoms are not described

NDPhD

The term “physical dependence” is used in the package insert, but is not
otherwise described or defined

NDPsD

The term “psychological dependence is used in the package insert, but is
not otherwise described or defined.

NDTol

The term “tolerance” is used in the package insert, but is not otherwise
described or defined

NDWD

The term “withdrawal” is used in the package insert, but is not otherwise
described or defined

None

The package insert contains no information on drug abuse or dependence
potential

NTPW

There is a warning against the use of the drug or certain dosage forms of
the drug in non-tolerant patients

OnOffse+

The package insert states that the onset and offset of the drug indicate
that it has increased potential for abuse

PdD+rab

Physical dependence has been seen in dogs and rabbits

PhD+dog

The package insert states that physical dependence occurred in dogs

PID/C

Patient information in the package insert contains a warning against
abrupt discontinuation of the drug
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PIDDD

Patient information in the package insert discusses, describes, or defines
“drug dependence”

PIDTol

Patient information in the package insert discusses, describes, or defines
“tolerance”

PIDWD

Patient information in the package insert discusses, describes, or defines
“withdrawal”

PIEqDepAd

Patient information in the package insert equated “dependence” with
“addiction”

PIHxDACa

Patient information in the package insert states that the drug should be
used with caution in patients with a history of drug abuse

PIMild

The patient information in the package insert was rated to have a mild
warning about drug abuse potential

PIMod

The patient information in the package insert was rated to have a
moderate warning about drug abuse potential

PISch

The FDA Controlled Substance Schedusv is given in the patient
information of the package insert

PIStBehW

The patient information of the package insert contains a warning that the
drug may cause strange behavior

PIStrong

The patient information of the package insert was rated to have a strong
warning about drug abuse potential

PITellMD

The patient information of the package insert instructs the patient to tell
his or her doctor if the patient had a history of drug abuse or was
currently abusing drugs

PregW

The package insert contains a warning against use in pregnancy

RareAb

The package insert states that abuse of the drug was rare

RareAd

The package insert states that addiction to the drug is rare when used in
the medical setting appropriately or that iatrogenic addiction to the drug
is rare

RareDep

The package insert states that “dependence” on the drug is rare

RareWD

The package insert states that withdrawal symptoms rarely occur with
discontinuation of the drug

Refer

The section dedicated to drug abuse and dependence information refers
the reader to another section in the package insert

Restricted

The package insert states that the use of the drug is restricted and gives
information on the restrictions for use

S&Eun

Safety and efficacy data for chronic condition are unavailable

SA-

The drug was not self-administered

SAP+

The drug was self-administered by primates

Sch

The FDA Controlled Substance Schedule is given in the package insert

StBehW

The package insert states that strange behavior may occur with use of the
drug

Steps

The package insert gives steps to take in order to prevent abuse or
diversion of the drug
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TimePhD

The package insert estimates how long it takes for physical dependence
to occur

TimeTol

The package insert estimates how long it takes to develop tolerance to
the drug

TolPtD

The package insert defines a “tolerant patient”

TolPtND

The package insert uses the term “tolerant patient” but does not
otherwise define it

TrtAdNoRole

The package insert asserts that the drug has no role in the treatment of
drug addiction

TrtODT/N

Treatment of overdose of tolerant and/or non-tolerant patients is
described
The package insert gives information on how to treat physical
dependence on the drug

TrtPhD
TrtTol

The package insert gives information on how to treat tolerance

TrtWD

The package insert gives information on to treat withdrawal symptoms

Wmild

The researcher rated the warning about drug abuse potential as mild

Wmod

The researcher rated the warning about drug abuse potential as moderate

Wstrong

The researcher rated the warning about drug abuse potential as strong
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Patient case scenarios used in survey

Case 1 (No Hx, Cancer pain)
A 38 year old Caucasian male is presenting to you with increasing pain, a history of
metastatic cancer, and no longer wishes to receive radiation or chemotherapy. He has no
history of psychoactive substance abuse. Previously, another physician has prescribed the
medication associated with the following package insert information:
Case 2 (No Hx, CNMP, U)
A 38 year old Caucasian male presents to you with complaints of lower back pain that
started about 6 months ago. Diagnostic tests have revealed no structural abnormalities. At
this time, the cause of the pain is unknown. The patient has no history of psychoactive
substance abuse. Previously, another physician has prescribed the medication associated
with the following package insert information:
Case 3 (No Hx, CNMP, K)
A 38 year old Caucasian male presents to you with increasing hip pain from osteoarthritis
not relieved by 1000 mg acetaminophen four times daily, nor by 800 mg ibuprofen three
times daily. He has no history of psychoactive substance abuse. Previously, another
physician has prescribed the medication associated with the following package insert
information:
Case 4 (No Hx, Acute)
A 38 year old Caucasian male follows up with you after being seen in the emergency
room 3 days ago for a broken ankle. He has no history of psychoactive substance abuse.
The physician in the emergency room prescribed the drug associated with the following
package insert information:
Case 5 (Past Hx, Cancer pain)
A 38 year old Caucasian male is presenting to you with increasing pain, a history of
metastatic cancer, and no longer wishes to receive radiation or chemotherapy. The patient
has a prior history of psychoactive substance abuse, but has not used in the last 5 years.
Previously, another physician has prescribed the medication associated with the
following package insert information:
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Case 6 (Past Hx, CNMP, U)
A 38 year old Caucasian male presents to you with complaints of lower back pain that
started about 6 months ago. Diagnostic tests have revealed no structural abnormalities. At
this time, the cause of the pain is unknown. The patient has a prior history of
psychoactive substance abuse, but has not used in the last 5 years. Previously, another
physician has prescribed the medication associated with the following package insert
information:
Case 7 (Past Hx, CNMP, K)
A 38 year old Caucasian male presents to you with increasing hip pain from osteoarthritis
not relieved by 1000 mg acetaminophen four times daily, nor by 800 mg ibuprofen three
times daily. The patient has a prior history of psychoactive substance abuse, but has not
used in the last 5 years. Previously, another physician has prescribed the medication
associated with the following package insert information:
Case 8 (Past Hx, Acute)
A 38 year old Caucasian male follows up with you after being seen in the emergency
room 3 days ago for a broken ankle. The patient has a prior history of psychoactive
substance abuse, but has not used in the last 5 years. The physician in the emergency
room prescribed the drug associated with the following package insert information:
Case 9 (Current use, Cancer pain)
A 38 year old Caucasian male is presenting to you with increasing pain, a history of
metastatic cancer, and no longer wishes to receive radiation or chemotherapy. He states
that he occasionally uses psychoactive substances for recreational purposes. Previously,
another physician has prescribed the medication associated with the following package
insert information:
Case 10 (Current use, CNMP, U)
A 38 year old Caucasian male presents to you with complaints of lower back pain that
started about 6 months ago. Diagnostic tests have revealed no structural abnormalities. At
this time, the cause of the pain is unknown. He states that he occasionally uses
psychoactive substances for recreational purposes. Previously, another physician has
prescribed the medication associated with the following package insert information:
Case 11 (Current use, CNMP, K)

130
A 38 year old Caucasian male presents to you with increasing hip pain from osteoarthritis
not relieved by 1000 mg acetaminophen four times daily, nor by 800 mg ibuprofen three
times daily. He states that he occasionally uses psychoactive substances for recreational
purposes. Previously, another physician has prescribed the medication associated with the
following package insert information:
Case 12 (Current use, Acute)
A 38 year old Caucasian male follows up with you after being seen in the emergency
room 3 days ago for a broken ankle. He states that he occasionally uses psychoactive
substances for recreational purposes. The physician in the emergency room prescribed the
drug associated with the following package insert information:
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Package insert excerpts used in survey

(Strong, Advice, No defs)
Drug A (PI#1): Severe dependence has occurred with Drug A. Do not prescribe Drug A
for patients who are suicidal or addiction-prone. Prescribe Drug A with caution for
patients taking tranquilizers or antidepressant drugs and patients who use alcohol in
excess. Tell your patients not to exceed the recommended dose and to limit their intake of
alcohol. Many of the Drug A-related deaths have occurred in patients with previous
histories of emotional disturbances or suicidal ideation or attempts as well as histories of
misuse of tranquilizers, alcohol, and other CNS-active drugs.
(Not strong, No advice, Defs)
Drug B (PI#2): As with other drugs in its class, Drug B may produce psychic
dependence, physical dependence, and tolerance may develop upon repeated
administration. However, psychic dependence is unlikely to develop when Drug B is used
for a short time for the treatment of pain. Physical dependence, the condition in which
continued administration of the drug is required to prevent the appearance of a
withdrawal syndrome, usually assumes clinically significant proportions only after
several weeks of continued use, although some mild degree of physical dependence may
develop after a few days of therapy. Tolerance, in which increasingly large doses are
required in order to produce the same degree of analgesia, is manifested initially by a
shortened duration of analgesic effect, and subsequently by decreases in the intensity of
analgesia. The rate of development of tolerance varies among patients.
(Strong, Advice, Defs)
Drug C (PI#3): Severe drug dependence and addiction have occurred with Drug C.
Addiction is a treatable disease characterized by drug-seeking behavior, craving, and
uncontrolled use. Abuse and addiction are separate and distinct from physical dependence
and tolerance. Addiction may not be accompanied by concurrent tolerance and
symptoms of physical dependence. The converse is also true. In addition, abuse can occur
in the absence of true addiction and is characterized by misuse for non-medical purposes,
often in combination with other psychoactive substances. Exercise careful record-keeping
of prescribing information, including quantity, frequency, and renewal requests. Do not
prescribe Drug C for patients who are suicidal or addiction-prone. Prescribe Drug C with
caution for patients taking tranquilizers or antidepressant drugs and patients who use
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alcohol in excess. Tell your patients not to exceed the recommended dose and to limit
their intake of alcohol.
(Strong, No advice, Defs)
Drug D (PI#4): Drug D has a high addiction potential and is subject to criminal
diversion. Drug addiction is a disease characterized by compulsive use, use for nonmedical purposes, and continued use despite harm or risk of harm. Drug addiction is
treatable utilizing a multi-disciplinary approach, but relapse is common. Addiction is
separate and distinct from physical dependence and tolerance. Physical dependence, the
condition in which continued administration of the drug is required to prevent the
appearance of a withdrawal syndrome, assumes clinically significant proportions only
after several weeks of continued use, although some mild degree of physical dependence
may develop after a few days of therapy. Upon abrupt discontinuation of Drug D,
withdrawal symptoms may occur. These symptoms may include: anxiety, sweating,
insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms,
piloerection, and rarely hallucinations.
(Not strong, Advice, Defs)
Drug E (PI#5): Drug E may induce psychic and physical dependence. Dependence and
abuse, including drug-seeking behavior and taking illicit actions to obtain the drug are not
limited to those patients with a prior history of dependence. The risk in patients with
substance abuse has been observed to be higher. Drug E is associated with craving and
tolerance development. Do not discontinue Drug E abruptly, as withdrawal symptoms
can occur. These symptoms may include: anxiety, sweating, insomnia, rigors, pain,
nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and rarely
hallucinations. Should withdrawal symptoms occur, reinstitute therapy with Drug E then
follow with a gradual, tapered dose reduction of the medication combined with
symptomatic support.
(Strong, No advice, No defs)
Drug F (PI#6): Drug F has been associated with severe psychological dependence,
physical dependence, and tolerance. However, psychic dependence is unlikely to develop
when Drug F is used for a short time for the treatment of pain. Withdrawal symptoms can
occur with abrupt discontinuation. Physical dependence assumes clinically significant
proportions only after several weeks of continued use, although some mild degree of
physical dependence may develop after a few days of therapy.
(Not strong, Advice, No defs)
Drug G (PI#7): Psychic dependence, physical dependence, and tolerance may develop
upon repeated administration of Drug G. Tell your patients not to exceed the
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recommended dose and to limit their intake of alcohol. Should withdrawal symptoms
occur upon discontinuation, reinstitute therapy with Drug G then follow with a gradual,
tapered dose reduction of the medication combined with symptomatic support.
(Not strong, No advice, No defs)
Drug H (PI#8): Like other drugs in its class, Drug H can produce drug dependence and
therefore has the potential for being abused. Psychic dependence, physical dependence,
and tolerance may develop upon repeated administration of Drug H. Physical dependence
assumes clinically significant proportions only after several weeks of continued use,
although some mild degree of physical dependence may develop after a few days of
therapy. The rate of development of tolerance varies among patients.
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Too much reading.
Warning for case 2 is too long.
Put more pity factor in letter to get better response since you aren’t paying us.
Questions for cases look like I’m going to have to fill out a grid.
Packet looks large and intimidating. Put in letter that there are only 5 questions for each
case scenario.
Too many cases if you aren’t paying us, or they are too long.
Letter says that you are focusing on package insert information but there are really only a
couple of questions about it in the questionnaire. Makes me wonder what you are really
after.
Make cases and warnings shorter or give fewer. I probably wouldn’t answer more than 3
or 4.
Don’t like the font on the cover page.
Will it be in color (printer didn’t have color but file was in color).
Too much about postcard/envelope procedure, and not enough about what to expect from
the questionnaire itself.
Giving essentially the same three cases twice and only changing the sex makes one of
your hypotheses obvious, and it has nothing to do with package insert information. Why
are you asking this?
More on format of questionnaire in letter because the packet looks like it’s more work
than it really is.
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Explain that C-II is highest abuse liability. I didn’t know what the question was asking
because I am not familiar with the schedules.
Looks like you are asking about too many factors and variables…is there any way you
can cut some of these out? Are they all necessary?
Layout is fine, maybe a booklet would be better if you could cut out some of the
wordiness; put the letter on letterhead.
Make sure you personally sign all the letters – it makes it more personal and they are
more likely to fill it out.
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*Note: Original cover letter was on letterhead and formatted to fit onto one page.
January 6, 2006
Dear Dr. _________

_____,

I am writing to ask your help with a survey I am conducting for my dissertation research
project at Virginia Commonwealth University’s School of Pharmacy. I am interested in
exploring physicians’ opinions about substance abuse information provided in package
inserts.
I am contacting a random sample from a registry of physicians in the state of Virginia
who are in various practice settings.
Enclosed in this packet are the questionnaire, an addressed and stamped envelope for its
return, and a postcard, also addressed and stamped. The purpose of this postcard is to
ensure that all responses are completely anonymous and to prevent repeat mailings. Once
your post-card is received, your information will be deleted from the mailing list. The
questionnaire should be mailed separately from the postcard.
The questionnaire consists of 4 case scenarios with 5 short questions, and then some
requested information about your views on addiction and dependence, sources you
consult for information, and general demographics. There are no correct or incorrect
answers, as I am interested in your opinions on topics related to drug abuse and
dependence information.
This survey is voluntary, and you would help me a great deal with my dissertation by
taking approximately 15 to 20 minutes to fill out and return the enclosed questionnaire.
If you have any questions or comments about the questionnaire or the survey study,
please feel free to contact me, either by phone at (804) 828-6096, or by email at
burroughslr@vcu.edu.
H

H

Thank you very much for assisting me with my dissertation research!
Sincerely,
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Lisa Burroughs Phipps, PharmD/PhD Candidate
Virginia Commonwealth University
Department of Pharmacy
410 N. 12th Street
PO Box 980533
Richmond, VA 23298-0533
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*Note: Follow-up cover letter was sent on letterhead and formatted to fit onto one page.
February 10, 2006
Dear Dr.
,
About four weeks ago, you should have received in the mail a questionnaire about drug
dependence and addiction. To the best of my knowledge, I have not yet received your
completed questionnaire.
As you may remember from the initial letter, I am writing to ask your help with a survey
I am conducting for my dissertation research project at Virginia Commonwealth
University’s School of Pharmacy. I am interested in exploring physicians’ opinions
about substance abuse information provided in package inserts. You were randomly
selected from a registry of physicians in the state of Virginia who are in various practice
settings.
I have provided you with a replacement questionnaire in case you no longer have the
original but would like to provide responses. Also enclosed are an addressed and stamped
envelope for returning the completed questionnaire, and a postcard, also addressed and
stamped. The purpose of this postcard is to ensure that all responses are completely
anonymous and to prevent repeat mailings. Once your post-card is received, your
information will be deleted from the mailing list. The questionnaire should be mailed
separately from the postcard. This will ensure that responses are anonymous.
The questionnaire consists of 4 case scenarios with 5 short questions, and then some
requested information about your views on addiction and dependence, sources you
consult for information, and general demographics. There are no correct or incorrect
answers, as I am interested in your opinions on topics related to drug abuse and
dependence information.

H

This survey is voluntary, and you would help me a great deal with my dissertation by
taking approximately 15 to 20 minutes to fill out and return the enclosed questionnaire.
If you have any questions or comments about the questionnaire or the survey study,
please feel free to contact me, either by phone at (804) 828-6096, or by email at
burroughslr@vcu.edu.
H
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Thank you very much for assisting me with my dissertation research!
Sincerely,

Lisa Burroughs Phipps, PharmD/PhD Candidate
Virginia Commonwealth University
Department of Pharmacy
410 N. 12th Street
PO Box 980533
Richmond, VA 23298-0533

140
I

Codebook for SPSS Analysis

APPENDIX I
Codebook for SPSS Analysis

SPSS Code
Resp#
QV
Case#
PI#
PIStr
PIAdv
PIDefs

Variable
Respondant #
Questionnaire version
Patient case
Package insert excerpt
Strength of warning
Advice in package insert
Definitions in package insert

PtPain

Type of pain

PtHx

Patient substance abuse history

Comf
Ref
Rx
Useful
Sch

Comfort level with prior
physician’s prescription
Refill likelihood
Prescribe if first physician?
Insert information useful?
Physician-rated schedule for drug

SrManD
SrMan
SrDICD
SrDIC
SrIntD
SrInt
SrPID

Source manufacturer for DDAD
Source manufacturer for other info
Source drug info ctr for DDAD
Source drug info ctr for other info
Source internet for DDAD
Source internet for other info
Source package insert for DDAD

Values
100-2414
1-24
1-12
1-8
0=not strong; 1=strong
0=no advice; 1=advice present
0=no definitions;
1=definitions given
1=Acute
2=Cancer
3=Chronic, nonmalignant, known
etiology (CNMK)
4=Chronic, nonmalignant, unknown
etiology (CNMU)
1=No history of substance abuse
2=Prior history of substance abuse
3=Current recreational use
For questions following scenarios:
0=Not at all
1=Not very
2=Somewhat
3=Definitely
2=C-II
3=C-III
4=C-IV
5=C-V
6=not controlled
For sources consulted for drug abuse
and dependence information
(DDAD), and for other information:
0=Never
1=Yearly
2=Monthly
3=Weekly
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SrPI
SrPDAD
SrPDA
SrRPhD
SrRPH
SrPDRD
SrPDR
SrOthD
SrOth
FacCSA
FacDef
FacHx
FacAdv
FacPain
FacWarn
DDAb
DDCr
DDDSB
DDPhyD
DDPsD
DDTol
DDWD
AddAb
AddCr
AddDSB
AddPhyD
AddPsD
AddTol
AddWD
MDGender
MDLiscYr
MDSpec
MDHxPer
MDRegion

Source package insert for other info
Source PDA for DDAD
Source PDA for other info
Source pharmacist for DDAD
Source pharmacist for other info
Source PDR for DDAD
Source PDR for other info
Other sources used for DDAD
Other sources used for other info
Importance of CSA schedule
Importance of definitions in insert
Importance of patient’s substance
abuse history
Importance of advice in insert
Importance of type of pain being
treated
Importance of package insert
warning strength
Abuse
Craving
Drug Seeking Behavior
Physical Dependence
Psychological Dependence
Tolerance
Withdrawal
Abuse
Craving
Drug Seeking Behavior
Physical Dependence
Psych Dependence
Tolerance
Withdrawal
Physician Gender
Physician Year of initial licensure
Physician Specialty
Estimated percent of patients with
known substance abuse history
Physician practice region

4=Daily

Rating importance of factors in
clinical decision making:
0=Not at all important
1=Somewhat unimportant
2=Somewhat important
3=Very important

Necessary for Drug Dependence:
0=no
1=yes

Necessary for Addiction:
0=no
1=yes

0=Female
1=Male
1940-2005
Entered as text
0-100
1=Northern
2=Western
3=Central
4=Tidewater
5=Southern
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MDLiscYrMV

6=Southwestern
7=Northern Neck
8=Eastern Shore
1940-2005

Licensure year with median
inserted for missing variables
MDhXPerMV
Estimated percent of patients with
0-100
known substance abuse history with
median inserted for missing
variables
DumPnAcute
Indicator for acute pain
0=not acute pain
1=acute pain
DumPnCancer
Indicator for cancer pain
0=not cancer pain
1=cancer pain
DumPnCNMK
Indicator for CNMK
0=not CNMK
1=CNMK
DumHxPast
Indicator for past substance abuse
0=not a past history
history
1=past history
DumHxCurr
Indicator for current substance use
0=not a current user
1=current user
MDSpecNum
Numerical category assignment for 0=Emergency medicine
medical specialty
1=Family practice
2=Internal medicine
3=Other
DumMDSpecFP Indicator for family practice
0=not family practice
1=family practice
DumMDSpecIM Indicator for internal medicine
0=not internal medicine
1=internal medicine
DumMDSpecOth Indicator for other specialty
0=not “other” specialty
1=other specialty
NewRegion
Collapsed category assignments for 0=Southwestern
practice region
1=Northern, Central, or Tidewater
(Urban)
2=Western, Southern, Northern
Neck, or Eastern Shore (Other rural)
DumReg1
Indicator for urban region
0=not urban
1=urban
DumReg2
Indicator for other rural region
0=not “other rural” region
1=other rural region
MDratedStr
Physician rated strength of package 0=not C-II
insert warning
1=C-II
DumUseful
Indicator for usefulness of package 0=not useful (not at all or not very)
insert information
1=useful (somewhat or definitely)
DVScale
Willingness to prescribe
Score=Comfort+Refill+Rx
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IntAcPast
IntAcCurr
IntCanPast
IntCanCurr
IntCNMKPast
IntCNMKCurr
IntStrPast
IntStrCurr

Acute pain, Past history
Acute pain, Current use
Cancer pain, Past history
Cancer pain, Current use
CNMK, Past history
CNMK, Current use
Strong warning, past history
Strong warning, current use

IntStrAc
IntStrCan
IntStrCNMK

Strong warning, acute pain
Strong warning, cancer pain
Strong warning, CNMK

Interaction terms are products for
indicator variables of pain type and
substance abuse history. Example:
Acute*Past
0=not acute pain and past history
1=acute pain and past history
Interaction terms are products for
indicator variables warning strength
and substance abuse history
Interaction terms are products for
indicator variables warning strength
and pain type
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APPENDIX J
Respondent comments

Note: Most respondents did not make additional comments. Comments that were made
are quoted below.
“Good luck!” (Four respondents wrote this)
“Good luck on your research! ☺”
“As previously noted, the package inserts are given to the patient and seldom carried by
the patient for the prescribing physicin’s review. Physicians are familiar with most all
analgesic medications and controlled substances with regard to their potential for
dependance/abuse. Decisions regarding what strength of pain medication to use is
multifactorial. Your first case scenario did not state what type metastatic cancer or what
type pain the patient was experiencing or anticipated length of life expectancy. Scneario
3 involved an ankle fracture which after splinted should not be extremely painful after 3
days; whereas arthritis (scenario 4) can be extremely painful depending on the type
arthritis and degree of swelling. Best wishes to you!”
“1) History of drug abuse/dependence should not deter a physician from treating acute
pain that is moderately severe or greater. More appropriate would be smaller #
pills/prescription. Close follow-up, planned duration of treatment, etc.” 2) For patients
with chronic pain, use of contracts between physician and patient can be helpful.”
“I tried to answer as if I were back in private practice. As an ER doc, I’m LESS likely to
rx highly controlled, MORE likely to be faced with DSB, and more likely to alleviate
suffering short-term (visit only) rather than Rx’ing meds that should be managed by a 1°
MD. I don’t write controlleds for chronic pain except terminal patients and will point to
package inserts in my explanation to patients.”
“- Package inserts often based on initial FDA studies and not reflections of general
clinical practice. – They are useful for initial start-up use and occasional to look up side
effects, warnings (preg risks, etc). I find I use them less and less. – The scenarios are
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hard to judge as I need more details (lots more) and need to know the particular drug to
really be able to make any decisions.”
“I am an internist who practices in the field of addiction treatment, therefore tolerance
and physical dependence do not equal your definitions to me. Drug abuse = misuse.
Drug dependence = addiction”
“I would be interested in reading a copy of your research results if available. Thanks.”
(Note: this physician signed the comment but it is not readable!)
“Each patient is different. Each doctor is different. Each pain is different. Package
inserts are helpful re: pharmacokinetics but worthless re: pharmacodynamics. Your
survey falls into the realm of not enough depth to be helpful but enough data to be
dangerous!”
“Good luck with your dissertation – would love to know your interpretation of data and
conclusions – let us know if you can.” (Note: this note was unsigned)
“Good luck, Lisa, and don’t forget to have fun.”
“Regarding the question of drug dependence, neither physical or psychological
dependence are necessary, but each are sufficient to make the diagnosis of dependence.”
“The DEA definitions of drug dependency are very scant and need to be simplified, so
they can be useful to clinicians. Your definitions are a lot more detailed and useful
alerting the physicians to the very real concerns of dependence for commonly prescribed
drugs.”
“The scenarios presented are helpful. There are many situations not discussed that may or
may not be deserving of study. These are individuals with criminal behavior, untreated
psychiatric states, etc. These should be referred to the drug abuse clinics for thorough
examination/treatment. Thank you for the opportunity to be of service.”
“I do not prescribe controlled substances in A/I practice, but your questions made me
realize I how much I encounter this problem although it raises suspicion on some phone
calls of denied meds. Good luck.”
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“In ER practice prescription of drugs with potential for addiction/dependence is quite
limited. When they are prescribed for pain only small amounts are usually prescribed.”
“I do not prescribe pain Rx to any sig °. I refer those people to pain tx ctr.”
“Prescription fraud laws should be tougher!”
“Your questions were good but don’t cover all situations – for example, depending on the
type of remote history of drug abuse, one might consider a short course of narcotics e.g.
2-3 days for someone with a broken ankle…for people with chronic pain, one would not
do this. Good luck with your dissertation!”
“Thank you, Lisa, for exploring these issues! Please go deeply into this whole issue.
Adequate pain control in our institutions/hospice programs/at home…in
brig…everywhere, is a big, big issue for us all. Try to separate the so-called ‘moral
issues’ from the behavioral and factual issues as much as possible. Good luck w/ your
degree!”
“The package insert questions may be skewed by the fact that in my practice I rarely see
package inserts.”
“Narcotics contract and log sheets have been real helpful to help in dealing with chronic
use of controlled substances for pain, etc.”
“The choice to prescribe the same med as presented in the case may have been made
easier if the patient had previously experienced relief while on this pill. For instance, in
case #3, if that had been included, I’d have √ed definitely.” (Note: Case #3 for this
questionnaire was cancer pain, prior history, drug A)
“Hope this has been helpful. Pain (chronic) management is a very complex assignment.
Good luck with this project.”
“1. I will prescribe a non Class II and class III analgesic if the clinical condition is
known and duration of use will be for less than 2 weeks. 2. For any patient presenting
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with a pain issue, a full work-up to pinpoint the etiology is first and foremost. Given no
dx – I will consider referral to a pain specialist (this step occurs after a rigorous search
(work-up) for the etiology of the pain. 3. In your 1st case, a hx of metastatic CA is not
enough. The CA must be proven and documentation in my hands. Then I would
prescribe but referer to a pain specialist ASAP and not manage the patient’s pain state.”
(Note: Case #1 for this questionnaire was cancer pain, no history, Drug A)
“My approach is to always refer pain syndromes to a pain specialist if there is no specific
clear reason of pain. I will treat self-limited pain associated with a specific clear dx that
would be self-limited. Any cancer-associated pain management is referred to heme/onc.
Palliative terminal pain management is coordinated with Hospice. Chronic pain
syndromes are always referred to a chronic pain management group or clinic.”
“My patients are all institutionalized due to mental retardation – hence drug/substance
abuse is very rare. I’m not too familiar with the Controlled Substance Schedule, but
know from experience the degree of potential dependence and addiction associated with
the limited number of analgesics I use. Drugs of abuse often make people feel better – at
least in the short-term – than psychotropic drugs. If from a public health perspective our
society is in some ways ‘toxic’ to our psychological well being (lack of a sense of
belonging, lack of community, alienation, lack of social cohesions), then drug abuse is a
symptom not only of an individual’s psychic ‘discomfort,’ but of the society’s ‘sickness.’
See Richard Wilkinson’s ‘Unhealthy Societies.’”
“ – Pain should be treated appropriately. – Know your patient (in practice for 1 month or
20 years, etc). – Document reasons (objective) for pain evaluation. – Document benefits
of therapy. – Follow up and careful monitoring. – Get family involved. – Etc etc.”
“I avoid even narcotic cough medications when possible.”
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APPENDIX K
Statistics for regression models

For Comfort model:
Predictor
Variable
Physician gender
Licensure year
% pts with history
Practice region
Urban
Other rural
Medical discipline Family practice
Internal medicine
Other
Type of pain
Acute
Cancer
CNMK
History of abuse
Past
Current
Warning strength
Advice present
Definitions given
Interaction terms
Acute*Past
Pain*History
Acute*Current
Cancer*Past
Cancer*Current
CNMK*Past
CNMK*Current

B
-0.093
0.011
0.000
0.091
0.166
-0.335
-0.342
-0.306
1.125
1.437
0.243
-0.423
-0.500
-0.270
-0.169
-0.196
-0.355
0.198
0.414
0.364
0.313
0.086

Std error
0.066
0.002
0.002
0.091
0.103
0.081
0.082
0.108
0.129
0.126
0.134
0.127
0.132
0.053
0.053
0.053
0.182
0.183
0.183
0.183
0.184
0.188

p-value
0.157
<0.001
0.908
0.317
0.106
<0.001
<0.001
0.005
<0.001
<0.001
0.070
0.001
<0.001
<0.001
0.002
<0.001
0.051
0.280
0.024
0.047
0.088
0.649
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For Refill model:
Predictor
Physician gender
Licensure year
% pts with history
Practice region
Medical discipline
Type of pain
History of abuse
Warning strength
Advice present
Definitions given
Interaction terms
Pain*History

Variable

Urban
Other rural
Family practice
Internal medicine
Other
Acute
Cancer
CNMK
Past
Current

Acute*Past
Acute*Current
Cancer*Past
Cancer*Current
CNMK*Past
CNMK*Current

B
0.040
0.011
-0.002
0.104
0.147
-0.177
-0.161
-0.193
0.901
1.585
0.290
-0.281
-0.374
-0.252
-0.103
-0.153
-0.435
-0.113
0.244
0.176
0.133
0.001

Std error
0.065
0.002
0.002
0.090
0.102
0.080
0.081
0.107
0.128
0.124
0.133
0.125
0.131
0.052
0.053
0.052
0.180
0.182
0.181
0.181
0.182
0.186

p-value
0.535
0.000
0.287
0.251
0.150
0.027
0.049
0.072
0.000
0.000
0.029
0.025
0.004
0.000
0.051
0.003
0.016
0.533
0.179
0.333
0.466
0.997
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For 1 physician model:
Predictor
Variable
Physician gender
Licensure year
% pts with history
Practice region
Urban
Other rural
Medical discipline Family practice
Internal medicine
Other
Type of pain
Acute
Cancer
CNMK
History of abuse
Past
Current
Warning strength
Advice present
Definitions given
Interaction terms
Acute*Past
Pain*History
Acute*Current
Cancer*Past
Cancer*Current
CNMK*Past
CNMK*Current

B
-0.081
0.012
0.002
0.132
0.231
-0.181
-0.239
-0.205
1.143
1.389
0.181
-0.370
-0.395
-0.276
-0.175
-0.175
-0.507
-0.051
0.376
0.273
0.224
-0.019

Std error
0.066
0.002
0.002
0.091
0.103
0.081
0.082
0.109
0.129
0.126
0.134
0.127
0.133
0.053
0.053
0.053
0.183
0.184
0.183
0.184
0.184
0.188

p-value
0.217
<0.001
0.195
0.148
0.026
0.025
0.004
0.061
<0.001
<0.001
0.178
0.004
0.003
<0.001
0.001
0.001
0.006
0.781
0.041
0.137
0.224
0.920
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For Willingness scale model:
Predictor
Variable
Physician gender
Licensure year
% pts with history
Practice region
Urban
Other rural
Medical discipline Family practice
Internal medicine
Other
Type of pain
Acute
Cancer
CNMK
History of abuse
Past
Current
Warning strength
Advice present
Definitions given
Interaction terms
Acute*Past
Pain*History
Acute*Current
Cancer*Past
Cancer*Current
CNMK*Past
CNMK*Current

B
-0.134
0.034
<0.001
0.327
0.546
-0.693
-0.742
-0.710
3.170
4.411
0.713
-1.075
-1.269
-0.797
-0.448
-0.524
-1.298
0.025
1.034
0.816
0.670
0.067

Std error
0.179
0.006
0.005
0.249
0.281
0.220
0.225
0.297
0.351
0.343
0.365
0.346
0.362
0.145
0.146
0.144
0.497
0.501
0.499
0.500
0.501
0.512

p-value
0.453
<0.001
0.962
0.189
0.052
0.002
0.001
0.017
<0.001
<0.001
0.051
0.002
<0.001
<0.001
0.002
<0.001
0.009
0.960
0.039
0.103
0.181
0.896
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